

Volume 45, Number 23
Pages 1827–1948
December 1, 2020

SALUS POPULI SUPREMA LEX ESTO

“The welfare of the people shall be the supreme law.”



JOHN R. ASHCROFT
SECRETARY OF STATE

MISSOURI
REGISTER

The *Missouri Register* is an official publication of the state of Missouri, under the authority granted to the secretary of state by sections 536.015 and 536.033, RSMo. Reproduction of rules is allowed; however, no reproduction shall bear the name *Missouri Register* or “official” without the express permission of the secretary of state.

The *Missouri Register* is published semi-monthly by

SECRETARY OF STATE

JOHN R. ASHCROFT

Administrative Rules Division

James C. Kirkpatrick State Information Center

600 W. Main

Jefferson City, MO 65101

(573) 751-4015

EDITOR-IN-CHIEF

CURTIS W. TREAT

•

MANAGING EDITOR

JOHN C. STEGMANN

•

EDITOR

VONNE KILBOURN

•

ASSOCIATE EDITOR

JENNIFER ALEX MOORE

•

PUBLICATION SPECIALIST

JACQUELINE D. WHITE

•

ADMINISTRATIVE AIDE

TAMMY WINKELMAN

ISSN 0149-2942

The *Missouri Register* and *Code of State Regulations* (CSR) are available on the Internet. The Register address is sos.mo.gov/adrules/moreg/moreg and the CSR is sos.mo.gov/adrules/csr/csr. The Administrative Rules Division may be contacted by email at rules@sos.mo.gov.

The secretary of state's office makes every effort to provide program accessibility to all citizens without regard to disability. If you desire this publication in alternate form because of a disability, please contact the Division of Administrative Rules, PO Box 1767, Jefferson City, MO 65102, (573) 751-4015. Hearing impaired citizens should contact the director through Missouri relay, (800) 735-2966.



IN THIS ISSUE:

EMERGENCY RULES

Department of Public Safety
Peace Officer Standards and Training Program1831

Department of Revenue
Director of Revenue1832

Department of Health and Senior Services
Division of Regulation and Licensure1837

Department of Commerce and Insurance
State Board of Pharmacy1851

Missouri Consolidated Health Care Plan
Health Care Plan1852

EXECUTIVE ORDERS1860

PROPOSED RULES

Department of Elementary and Secondary Education
Division of Learning Services1863

Department of Public Safety
Missouri State Highway Patrol1868

Department of Revenue
Director of Revenue1879

Department of Health and Senior Services
Division of Regulation and Licensure1883

Department of Commerce and Insurance
Missouri State Board of Accountancy1897
Behavior Analyst Advisory Board1902
Board of Examiners for Hearing Instrument Specialists . . .1902
State Board of Pharmacy1903
State Committee of Psychologists1904
State Committee for Social Workers1905

Missouri Consolidated Health Care Plan
Health Care Plan1907

ORDERS OF RULEMAKING

Department of Agriculture
Animal Health1913

Department of Elementary and Secondary Education
Division of Learning Services1913

Department of Public Safety
Peace Officer Standards and Training Program1916

Department of Health and Senior Services
Division of Regulation and Licensure1917

Department of Commerce and Insurance
Life, Annuities and Health1917
Insurance Licensing1920
State Board of Embalmers and Funeral Directors1920
Public Service Commission1921

IN ADDITIONS

Office of Administration
State Officials' Salary Compensation Schedule1926

Department of Health and Senior Services
Missouri Health Facilities Review Committee1929

DISSOLUTIONS1930

SOURCE GUIDES

RULE CHANGES SINCE UPDATE1933

EMERGENCY RULES IN EFFECT1938

EXECUTIVE ORDERS1940

REGISTER INDEX1942

Register Filing Deadlines	Register Publication Date	Code Publication Date	Code Effective Date
August 3, 2020 August 17, 2020	September 1, 2020 September 15, 2020	September 30, 2020 September 30, 2020	October 30, 2020 October 30, 2020
September 1, 2020 September 15, 2020	October 1, 2020 October 15, 2020	October 31, 2020 October 31, 2020	November 30, 2020 November 30, 2020
October 1, 2020 October 15, 2020	November 2, 2020 November 16, 2020	November 30, 2020 November 30, 2020	December 30, 2020 December 30, 2020
November 2, 2020 November 16, 2020	December 1, 2020 December 15, 2020	December 31, 2020 December 31, 2020	January 30, 2021 January 30, 2021
December 1, 2020 December 15, 2020	January 4, 2021 January 15, 2021	January 29, 2021 January 29, 2021	February 28, 2021 February 28, 2021
January 4, 2021 January 15, 2021	February 1, 2021 February 16, 2021	February 28, 2021 February 28, 2021	March 30, 2021 March 30, 2021
February 1, 2021 February 16, 2021	March 1, 2021 March 15, 2021	March 31, 2021 March 31, 2021	April 30, 2021 April 30, 2021
March 1, 2021 March 15, 2021	April 1, 2021 April 15, 2021	April 30, 2021 April 30, 2021	May 30, 2021 May 30, 2021

Documents will be accepted for filing on all regular workdays from 8:00 a.m. until 5:00 p.m. We encourage early filings to facilitate the timely publication of the *Missouri Register*. Orders of Rulemaking appearing in the *Missouri Register* will be published in the *Code of State Regulations* and become effective as listed in the chart above. Advance notice of large volume filings will facilitate their timely publication. We reserve the right to change the schedule due to special circumstances. Please check the latest publication to verify that no changes have been made in this schedule. To review the entire year's schedule, please check out the website at sos.mo.gov/adrules/pubsched.

HOW TO CITE RULES AND RSMO

RULES

The rules are codified in the *Code of State Regulations* in this system–

Title		Division	Chapter	Rule
3	CSR	10-	4	.115
Department	<i>Code of State Regulations</i>	Agency Division	General area regulated	Specific area regulated

and should be cited in this manner: 3 CSR 10-4.115.

Each department of state government is assigned a title. Each agency or division in the department is assigned a division number. The agency then groups its rules into general subject matter areas called chapters and specific areas called rules. Within a rule, the first breakdown is called a section and is designated as (1). Subsection is (A) with further breakdown into paragraphs 1., subparagraphs A., parts (I), subparts (a), items I. and subitems a.

The rule is properly cited by using the full citation, for example, 3 CSR 10-4.115 NOT Rule 10-4.115.

Citations of RSMo are to the *Missouri Revised Statutes* as of the date indicated.

Code and Register on the Internet

The *Code of State Regulations* and *Missouri Register* are available on the Internet.

The *Code* address is sos.mo.gov/adrules/csr/csr

The *Register* address is sos.mo.gov/adrules/moreg/moreg

These websites contain rulemakings and regulations as they appear in the *Code* and *Registers*.

Rules appearing under this heading are filed under the authority granted by section 536.025, RSMo. An emergency rule may be adopted by an agency if the agency finds that an immediate danger to the public health, safety, or welfare, or a compelling governmental interest requires emergency action; follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances; follows procedures which comply with the protections extended by the *Missouri* and the *United States Constitutions*; limits the scope of such rule to the circumstances creating an emergency and requiring emergency procedure, and at the time of or prior to the adoption of such rule files with the secretary of state the text of the rule together with the specific facts, reasons, and findings which support its conclusion that there is an immediate danger to the public health, safety, or welfare which can be met only through the adoption of such rule and its reasons for concluding that the procedure employed is fair to all interested persons and parties under the circumstances.

Rules filed as emergency rules may be effective not less than ten (10) business days after filing or at such later date as may be specified in the rule and may be terminated at any time by the state agency by filing an order with the secretary of state fixing the date of such termination, which order shall be published by the secretary of state in the *Missouri Register* as soon as practicable.

All emergency rules must state the period during which they are in effect, and in no case can they be in effect more than one hundred eighty (180) calendar days or thirty (30) legislative days, whichever period is longer. Emergency rules are not renewable, although an agency may at any time adopt an identical rule under the normal rulemaking procedures.

**Title 11—DEPARTMENT OF PUBLIC SAFETY
Division 75—Peace Officer Standards and
Training Program
Chapter 15—Continuing Education**

EMERGENCY AMENDMENT

11 CSR 75-15.010 Continuing Education Requirement. The director is adding a new section (9) and renumbering as needed.

PURPOSE: This emergency amendment adds de-escalation and implicit bias to the topics for continuing law enforcement education.

EMERGENCY STATEMENT: This emergency amendment specifies that of the twenty-four (24) hours of continuing education required annually for peace officers, one (1) credit hour is to cover the topic of de-escalation and one (1) credit hour is to cover the topic of implicit bias.

An emergency amendment will allow these training standards to go into effect during the 2021 reporting year. Without an emergency amendment, officers will not be required to receive training in these areas until 2022, and they will not have to report compliance until 2023.

This emergency amendment is necessary due to an immediate danger to the public health, safety or welfare: Incidents in which law enforcement officers have failed to properly de-escalate a situation or have exhibited bias have resulted in injury or death to individuals interacting with law enforcement; civil unrest that endangers the

lives, property, and security of the public and law enforcement officers has followed these incidents; and improved training of officers will help to prevent such incidents in the future.

This emergency amendment is also necessary to preserve a compelling government interest by helping to eliminate bias in policing and improve relations between law enforcement and the communities they serve. A recent national survey showed that confidence in police is at its lowest recorded point, with only nineteen percent (19%) of Black adults reporting “a great deal” or “quite a lot” of confidence in the police. According to a database of police shootings, on-duty law enforcement officers shot and killed twenty-eight (28) people in Missouri in 2019. Forty-six percent (46%) of these individuals with a known race who were shot and killed were Black, but only twelve percent (12%) of Missourians are Black.

This emergency amendment follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances, including the following: The Peace Officer Standards and Training (POST) Commission conducted surveys of the public and law enforcement, and held public listening sessions to discuss the results of these surveys. Twenty-five percent (25%) of the public survey respondents expressing concern about law enforcement identified inadequate training as their primary concern, and both the public and law enforcement surveys identified de-escalation as the top area necessitating additional training. After receiving this feedback, the POST Commission unanimously approved this amendment at a public meeting on October 5, 2020.

A proposed amendment, which covers the same material, was published in the November 16, 2020, issue of the *Missouri Register*. The scope of this emergency amendment is limited to the circumstances creating the emergency and complies with the protections extended in the *Missouri* and *United States Constitutions*. The director believes this emergency amendment is fair to all interested persons and parties under the circumstances. This emergency amendment was filed October 16, 2020, becomes effective January 1, 2021, and expires June 29, 2021.

(9) Every peace officer is to obtain at least one (1) credit hour of CLEE training covering the topic of de-escalation and one (1) credit hour of CLEE training covering the topic of implicit bias.

[(9)](10) At the conclusion of each CLEE period, the director is to determine the compliance of each peace officer pursuant to this rule. Each peace officer is responsible for reporting and demonstrating compliance to the director.

[(10)](11) A peace officer may apply to the director for a modification or waiver of the CLEE requirement for any CLEE period in which the officer takes official state or federal military leave of absence or in which the director determines that the officer was unable to comply with the CLEE training standard due to a documented medical condition. Any determination made by the director pursuant to this rule is subject to review only pursuant to section 536.150, RSMo.

[(11)](12) Any peace officer who fails to comply with this rule is subject to discipline pursuant to section 590.080.1.(6), RSMo.

AUTHORITY: sections 590.030.5.(1), 590.050, and 590.190, RSMo 2016. Original rule filed May 1, 2002, effective Oct. 30, 2002. For intervening history, please consult the *Code of State Regulations*. Emergency amendment filed Oct. 16, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material was published in the November 16, 2020, issue of the *Missouri Register*.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500)

in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

**Title 11—DEPARTMENT OF PUBLIC SAFETY
Division 75—Peace Officer Standards and
Training Program
Chapter 15—Continuing Education**

EMERGENCY AMENDMENT

11 CSR 75-15.020 Minimum Standards for Continuing Education Training. The director is amending sections (2) and (4).

PURPOSE: This emergency amendment requires that continuing law enforcement education training relating to de-escalation or implicit bias be designated as such.

EMERGENCY STATEMENT: This emergency amendment requires that training on the topics of de-escalation or implicit bias be designated as such. The director has filed an emergency amendment to 11 CSR 75-15.010 specifying that peace officers must receive training each year in de-escalation and implicit bias. This is a corresponding amendment.

This emergency amendment will allow for training that will satisfy the requirements set forth in the emergency amendment to 11 CSR 75-15.010 to be designated as such during the 2021 reporting year. Without an emergency amendment, the training will not be required to be designated as satisfying these requirements until the 2022 reporting year.

This emergency amendment is necessary due to an immediate danger to the public health, safety or welfare: Improved training of officers will help prevent incidents that result in injury or death to individuals interacting with law enforcement, and civil unrest that follows such incidents.

This emergency amendment is also necessary to preserve a compelling government interest by allowing peace officers to understand which courses will satisfy the new training requirements that have become effective with the amendment to 11 CSR 75-15.010.

This emergency amendment follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances, including the following: The Peace Officer Standards and Training (POST) Commission conducted surveys of the public and law enforcement, and held public listening sessions to discuss the results of these surveys. After receiving this feedback, the POST Commission unanimously approved this amendment at a public meeting on October 5, 2020.

A proposed amendment, which covers the same material, was published in the November 16, 2020, issue of the *Missouri Register*. The scope of this emergency amendment is limited to the circumstances creating the emergency and complies with the protections extended in the *Missouri* and *United States Constitutions*. The director believes this emergency amendment is fair to all interested persons and parties under the circumstances. This emergency amendment was filed October 19, 2020, becomes effective January 1, 2021, and expires June 29, 2021.

(2) All CLEE training is to be designated according to curricula area. CLEE training relating to **de-escalation, implicit bias**, racial profiling and firearms is to also be designated as such, in addition to being designated by curricula area.

(4) Upon successful completion of the requirements of any CLEE course, the provider of the training is to report to the director the successful completion of the CLEE course by the trainee in a method to

be determined by the director and is to present each trainee a certificate bearing—

- (A) The provider's name;
- (B) The course name;
- (C) The total number of CLEE credit hours earned;
- (D) A breakdown of CLEE credit hours earned by curricula area;
- (E) The number of **de-escalation, implicit bias**, racial profiling or firearms CLEE credit hours earned, if any;
- (F) The trainee's name;
- (G) The name of the individual responsible for general administration of the course; and
- (H) The date and location the course was presented.

AUTHORITY: sections 590.030.5.(1), 590.050, and 590.190, RSMo 2016. Original rule filed May 1, 2002, effective Oct. 30, 2002. For intervening history, please consult the *Code of State Regulations*. Emergency amendment filed Oct. 19, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material was published in the November 16, 2020, issue of the *Missouri Register*.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

**Title 12—DEPARTMENT OF REVENUE
Division 10—Director of Revenue
Chapter 41—General Tax Provisions**

EMERGENCY AMENDMENT

12 CSR 10-41.010 Annual Adjusted Rate of Interest. The department proposes to amend section (1).

PURPOSE: This emergency amendment establishes the annual adjusted rate of interest to be implemented and applied on taxes remaining unpaid during 2021.

EMERGENCY STATEMENT: The director of revenue is mandated to establish not later than October 22 annual adjusted rate of interest based upon the adjusted prime rate charged by banks during September of that year as set by the Board of Governors of the Federal Reserve rounded to the nearest full percent. This emergency amendment is necessary to ensure public awareness and to preserve a compelling governmental interest requiring an early effective date in that the amendment informs the public of the established rate of interest to be paid on unpaid amounts of taxes for the 2020 calendar year. A proposed amendment, that covers the same material, is published in this issue of the *Missouri Register*. The director has limited the scope of the emergency amendment to the circumstances creating the emergency. The director has followed procedures calculated to assure fairness to all interested persons and parties and has complied with protections extended by the *Missouri* and *United States Constitutions*. Emergency amendment filed October 19, 2020, effective January 1, 2020, expires June 29, 2021.

(1) Pursuant to section 32.065, RSMo, the director of revenue upon official notice of the average predominant prime rate quoted by commercial banks to large businesses, as determined and reported by the Board of Governors of the Federal Reserve System in the Reserve Statistical Release H.15(519) for the month of September of each year has set by administrative order the annual adjusted rate of interest to be paid on unpaid amounts of taxes during the succeeding calendar year as follows:

Calendar Year	Rate of Interest on Unpaid Amounts of Taxes
1995	12%
1996	9%
1997	8%
1998	9%
1999	8%
2000	8%
2001	10%
2002	6%
2003	5%
2004	4%
2005	5%
2006	7%
2007	8%
2008	8%
2009	5%
2010	3%
2011	3%
2012	3%
2013	3%
2014	3%
2015	3%
2016	3%
2017	4%
2018	4%
2019	5%
2020	5%
2021	3%

AUTHORITY: section 32.065, RSMo 2016. Emergency rule filed Oct. 13, 1982, effective Oct. 23, 1982, expired Feb. 19, 1983. Original rule filed Nov. 5, 1982, effective Feb. 11, 1983. For intervening history, please consult the **Code of State Regulations**. Emergency amendment filed Oct. 19, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material is published in this issue of the **Missouri Register**.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

**FISCAL NOTE
PUBLIC COST**

I. RULE NUMBER

Rule Number and Name:	12 CSR 10-41.010 Annual Adjusted Rate of Interest
Type of Rulemaking:	Emergency Amendment

II. SUMMARY OF FISCAL IMPACT

Estimate of the number of entities by class which would likely be affected by adoption of the proposed rule:	Classification by types of the business entities which would likely be affected:	Estimate in the aggregate as to the cost of compliance with the rule by the affected entities:
Any taxpayer with delinquent tax.	Any taxpayer with delinquent tax.	<i>This proposed amendment will not cost public entities more than five hundred dollars (\$500) in the aggregate. The 2021 interest rate imposed on delinquent taxes is less than that imposed in 2020.</i>

III. WORKSHEET

The proposed amendment establishes the rate of interest for 2021 at three percent (3%), which is less than the rate in 2020.

This proposed amendment will not cost public entities more than five hundred dollars (\$500) in the aggregate. Because the 2021 interest rate imposed on delinquent taxes is less than the rate imposed in 2020, the interest rate will be lower on each \$100 of delinquent taxes to public entities.

Interest on Delinquent Taxes Paid to Department of Revenue

	Current Rule 5.00%	Proposed Amendment 3.00%
Example:		
Past due tax amount	\$100.00	\$100.00
Interest Amount (%)	\$5.00	\$3.00
Total Amount Due	\$105.00	\$103.00

IV. ASSUMPTIONS

Pursuant to Section 32.065, RSMo, the Director of Revenue is mandated to establish an annual adjusted rate of interest based upon the adjusted prime rate charged by banks during September of that year, as set by the Board of Governors of the Federal Reserve, rounded to the nearest full percentage. The actual bank prime loan rate noted by the Federal Reserve in 2020 is three point two five percent (3.25%). The actual bank prime loan rate noted by the Federal Reserve in 2019 was five point two five percent (5.25%).

**FISCAL NOTE
PRIVATE COST**

I. RULE NUMBER

Rule Number and Name:	12 CSR 10-41.010 Annual Adjusted Rate of Interest
Type of Rulemaking:	Emergency Amendment

II. SUMMARY OF FISCAL IMPACT

Estimate of the number of entities by class which would likely be affected by adoption of the proposed rule:	Classification by types of the business entities which would likely be affected:	Estimate in the aggregate as to the cost of compliance with the rule by the affected entities:
Any taxpayer with delinquent tax.	Any taxpayer with delinquent tax.	<i>This proposed amendment will not cost private entities more than five hundred dollars (\$500) in the aggregate. The 2021 interest rate imposed on delinquent taxes is less than that imposed in 2020. The actual number of affected taxpayers is unknown.</i>

III. WORKSHEET

The proposed amendment establishes the rate of interest for 2021 at three percent (3%), which is less than the rate in 2020.

This proposed amendment will not cost private entities more than five hundred dollars (\$500) in the aggregate. Because the 2021 interest rate imposed on delinquent taxes is less than the rate imposed in 2020, the interest rate will be lower on each \$100 of delinquent taxes to private entities. The actual number of affected taxpayers is unknown.

Interest on Delinquent Taxes Paid to Department of Revenue

	Current Rule 5.00%	Proposed Amendment 3.00%
Example:		
Past due tax amount	\$100.00	\$100.00
Interest Amount (%)	\$5.00	\$3.00
Total Amount Due	\$105.00	\$103.00

IV. ASSUMPTIONS

Pursuant to Section 32.065, RSMo, the Director of Revenue is mandated to establish an annual adjusted rate of interest based upon the adjusted prime rate charged by banks during September of that year, as set by the Board of Governors of the Federal Reserve, rounded to the nearest full percentage. The

actual bank prime loan rate noted by the Federal Reserve in 2020 is three point two five percent (3.25%). The actual bank prime loan rate noted by the Federal Reserve in 2019 was five point two five percent (5.25%).

Title 19—DEPARTMENT OF HEALTH AND SENIOR SERVICES
Division 30—Division of Regulation and Licensure
Chapter 1—Controlled Substances

EMERGENCY AMENDMENT

19 CSR 30-1.002 Schedules of Controlled Substances. The department is amending section (1).

PURPOSE: This emergency amendment updates the Schedules of Controlled Substances to be consistent with 21 CFR Part 1308.

EMERGENCY STATEMENT: The United States Department of Justice Drug Enforcement Administration (DEA) continually evaluates substances to determine their clinical application and potential for abuse. Based on their evaluation, the DEA issues scheduling actions to place substances in the appropriate controlled substance schedules. The majority of these scheduling actions consist of temporarily and permanently scheduling newly-discovered illicit substances in Schedule I. Proper scheduling of these substances allow law enforcement to take action to prevent the further distribution of these substances. Scheduling substances in Schedules II-V allows practitioners to be informed about the potential for addiction/abuse of the substances and prescribe the substances appropriately. Section 195.015, RSMo charges the department with similarly controlling substances as they are controlled under federal law. This section also now (as of August 28, 2020) states that the department shall submit emergency rules to the secretary of state within thirty (30) days of a federal scheduling action to allow for similar inclusion, rescheduling, or deletion of controlled substances with this schedule. While this time frame is difficult to achieve given the various approvals and reviews needed prior to the department scheduling any rule with the secretary of state, the department still acts to effectuate these scheduling actions as quickly as possible. This emergency amendment includes all federal scheduling actions since the last amendment of this rule in 2019. The scope of this emergency amendment is limited to the circumstances creating the emergency and complies with the protections extended in the Missouri and United States Constitutions. The Department of Health and Senior Services believes this emergency amendment is fair to all interested persons and parties under the circumstances. A proposed amendment, which covers this same material, is published in this issue of the Missouri Register. Subject to section 536.025, this emergency amendment was filed October 30, 2020, becomes effective November 16, 2020, and expires May 14, 2021.

(1) Schedules of Controlled Substances.

(A) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the Drug Enforcement Administration (DEA) Controlled Substances Code Number set forth opposite it.

1. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:

- A. Acetyl-alpha-methylfentanyl
(N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide) 9815
- B. Acetylmethadol 9601
- C. Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) 9821
- D. N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, its isomers, esters, ethers,

- salts and salts of isomers, esters and ethers (Other names: acryl fentanyl, acryloylfentanyl) 9811
- E. AH-7921(3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551
- F. Allylprodine 9602
- G. Alphacetylmethadol (except levoalphacetylmethadol also known as levo-alpha acetylmethadol levothadyl acetate or LAAM) 9603
- H. Alphameprodine 9604
- I. Alphamethadol 9605
- J. Alpha-methylfentanyl (N-1-(alphamethyl-beta-phenethyl)-ethyl-4-piperidinyl) propionanilide; 1-(1-methyl-2-phenylethyl)-4 ((N-propanilido) piperidine) 9814
- K. Alpha-methylthiofentanyl (N-(1-methyl-2-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide) 9832
- L. Benzethidine 9606
- M. Betacetylmethadol 9607
- N. Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-phenylpropanamide) 9830
- O. Beta-hydroxy-3-methylfentanyl (other name: N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide) 9831
- P. N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide (Other names: beta-hydroxythiofentanyl) 9836**
- [P]/Q. Betameprodine 9608
- [Q]/R. Betamethadol 9609
- [R]/S. Betaprodine 9611
- [S]/T. Clonitazene 9612
- U. Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide) 9845**
- [T]/V. Dextromoramide 9613
- [U]/W. Diampromide 9615
- [V]/X. Diethylthiambutene 9616
- [W]/Y. Difenoxyin 9168
- [X]/Z. Dimenoxadol 9617
- [Y]/AA. Dimepheptanol 9618
- [Z]/BB. Dimethylthiambutene 9619
- [AA]/CC. Dioxaphetyl butyrate 9621
- [BB]/DD. Dipipanone 9622
- [CC]/EE. Ethylmethylthiambutene 9623
- [DD]/FF. Etonitazene 9624
- [EE]/GG. Etoxadine 9625
- [FF]/HH. N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other names: 4-fluoroisobutyryl

fentanyl, <i>para</i> - fluoroisobutyl fentanyl)	9824
/GG/II. <i>N</i> -(1-phenethylpiperidin- 4-yl)- <i>N</i> -phenylfuran-2- carboxamide (Other names: furan fentanyl)	9834
/HH/JJ. Furethidine	9626
/II/KK. Hydroxypethidine	9627
/JJ/LL. Ketobemidone	9628
/KK/MM. Levomoramide	9629
/LL/NN. Levophenacymorphan	9631
OO. Methoxyacetyl fentanyl (2-methoxy-<i>N</i>- (1-phenethylpiperidin-4-yl)-<i>N</i>- phenylacetamide	9825
/MM/PP. 3-Methylfentanyl (<i>N</i> -(3- methyl-1-(2-phenylethyl)- 4-piperidyl)- <i>N</i> - phenylpropanamide), its optical and geometric isomers, salts, and salts of isomers	9813
/NN/QQ. 3-Methylthiofentanyl (<i>N</i> - ((3-methyl-1-(2- thienyl)ethyl-4-piperidyl)- <i>N</i> -phenylpropanamide)	9833
/OO/RR. Morpheridine	9632
/PP/SS. MPPP (1-methyl-4-phenyl- 4-propionoxypiperidine)	9661
/QQ/TT. MT-45 (1-cyclohexyl- 4-(1,2-diphenylethyl) piperazine)	(9560)
/RR/UU. Noracymethadol	9633
/SS/VV. Norlevorphanol	9634
/TT/WW. Normethadone	9635
/UU/XX. Norpipanone	9636
/VV/YY. <i>N</i> -(2-fluorophenyl)-2- methoxy- <i>N</i> - (1-phenethylpiperidin-4- yl)acetamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: ocfentanil)	9838
ZZ. ortho-Fluorofentanyl (<i>N</i>-(2- fluorophenyl)-<i>N</i>-(1- phenethylpiperidin-4-yl) propionamide); other name: 2-fluorofentanyl)	9816
AAA. para-Fluorobutyl fentanyl (<i>N</i>- (4-fluorophenyl)-<i>N</i>-(1-phenethylpiperidin- 4-yl)butyramide)	9823
/WW/BBB. Para-fluorofentanyl(<i>N</i> - (4-fluorophenyl)- <i>N</i> - (1-(2-phenethyl)-4- piperidyl) propanamide	9812
/XX/CCC. PEPAP (1-(2-phenethyl)- 4-phenyl-4- acetoxypiperidine)	9663
/YY/DDD. Phenadoxone	9637
/ZZ/EEE. Phenampromide	9638
/AAA/FFF. Phenomorphan	9647
/BBB/GGG. Phenoperidine	9641
/CCC/HHH. Piritramide	9642
/DDD/III. Proheptazine	9643
/EEE/JJJ. Propерidine	9644
/FFF/KKK. Propiram	9649
/GGG/LLL. Racemoramide	9645

/HHH/MMM. <i>N</i> -(1-phenethylpiperidin- 4-yl)- <i>N</i> - phenyltetrahydrofuran-2- carboxamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: tetrahydrofuran fentanyl)	9843
---	------

/III/NNN. Thiofentanyl (<i>N</i> -phenyl- <i>N</i> - (1-(2-thienyl)ethyl-4- piperidyl)-propanamide	9835
--	------

/JJJ/OOO. Tilidine	9750
---------------------------	------

/KKK/PPP. Trimeperidine	9646
--------------------------------	------

2. Opium derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

A. Acetorphine	9319
B. Acetyldihydrocodeine	9051
C. Benzylmorphine	9052
D. Codeine methylbromide	9070
E. Codeine- <i>N</i> -Oxide	9053
F. Cyrenorphine	9054
G. Desomorphine	9055
H. Dihydromorphine	9145
I. Drotebanol	9335
J. Etorphine (except hydrochloride salt)	9056
K. Heroin	9200
L. Hydromorphanol	9301
M. Methyldesorphine	9302
N. Methyldihydromorphine	9304
O. Morphine methylbromide	9305
P. Morphine methylsulfonate	9306
Q. Morphine- <i>N</i> -Oxide	9307
R. Myrophine	9308
S. Nicocodeine	9309
T. Nicomorphine	9312
U. Normorphine	9313
V. Pholcodine	9314
W. Thebacon	9315

3. Opiate Similar Synthetic Substances. Substances scheduled by the United States Drug Enforcement Administration as substances that share a pharmacological profile similar to fentanyl, morphine, and other synthetic opioids, unless specifically excepted or unless listed in another schedule. These substances are:

A. Butyl fentanyl (<i>N</i> - (1-phenethylpiperidin-4-yl)- <i>N</i> -phenylbutyramide)	9822
B. U-47700 (3,4-Dichloro- <i>N</i> -[2-(dimethylamino) cyclohexyl]- <i>N</i> methylbenzamide)	9547

4. Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (For purposes of paragraph (1)(A)4. of this rule only, the term isomer includes the optical, position, and geometric isomers.):

A. Alpha-ethyltryptamine	7249
--------------------------	------

Some trade or other names: etryptamine; Monase; alpha-ethyl-1*H*-indole-3-ethenamine; 3-(2-aminobutyl)indole; alpha-ET; and AET;

B. 4-bromo-2,5- dimethoxyamphetamine	7391
---	------

Some trade or other names: 4-bromo-2, 5- dimethoxy-a-methylphenethylamine; 4-bromo- 2, 5-DMA;		Some trade and other names: <i>N, N</i> -Diethyltryptamine; DET;	
C. 4-bromo-2,5-dimethoxyphenethylamine	7392	BB. Dimethyltryptamine	
D. 2,5-dimethoxyamphetamine	7396	Some trade or other names: DMT;	7435
Some trade or other names: 2,5-dimethoxyamethylphenethylamine; 2,5-DMA;		CC. 5-methoxy- <i>N, N</i> -diisopropyltryptamine (other name: 5-MeODIPT)	7439
E. 2,5-dimethoxy-4-ethylamphetamine	7399	DD. Ibogaine	7260
Some trade or other names: DOET		Some trade and other names: 7-Ethyl- 6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6, 9-methano-5 <i>H</i> -pyrido [1',2':1,2] azepino[5,4-b] indole; Tabernanthe iboga;	
F. 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7)	7348	EE. Lysergic acid diethylamide	7315
G. 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P)	7524	FF. Marihuana	7360
H. 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E)	7509	Some trade or other names: marijuana;	
I. 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D)	7508	GG. Mescaline	7381
J. 2-(2,5-Dimethoxy-4-nitrophenyl) ethanamine (2C-N)	7521	HH. Parahexyl	7374
K. 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H)	7517	Some trade or other names: 3-Hexyl-1- hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl- 6 <i>H</i> -dibenzo[b,d]pyran; Synhexyl;	
L. 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C)	7519	II. Peyote	7415
M. 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2)	7385	Meaning all parts of the plant presently classified botanically as <i>Lophophora williamsii</i> Lemaire, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salt, derivative, mixture or preparation of such plant, its seeds or extracts;	
N. 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C-I)	7518	JJ. <i>N</i> -ethyl-3-piperidyl benzilate	7482
O. 2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C-T-4)	7532	KK. <i>N</i> -methyl-3-piperidyl benzilate	7484
P. 4-methoxyamphetamine	7411	LL. Psilocybin	7437
Some trade or other names: 4-methoxyamethylphenethylamine; paramethoxyamphetamine; PMA;		MM. Psilocyn	7438
Q. 5-methoxy-3,4-methylenedioxyamphetamine	7401	NN. Tetrahydrocannabinols naturally contained in a plant of the genus <i>Cannabis</i> (<i>cannabis</i> 7370 plant), as well as synthetic equivalents of the substances contained in the <i>cannabis</i> plant or in the resinous extractives of such plant, and/or synthetic substances, derivatives and their isomers, or both, with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following:	
R. 4-methyl-2,5-dimethoxyamphetamine	7395	(I) 1 cis or trans tetrahydrocannabinol and their optical isomers;	
Some trade and other names: 4-methyl-2, 5- dimethoxy-a-methylphenethylamine; DOM;and STP;		(II) 6 cis or trans tetrahydrocannabinol and their optical isomers;	
S. 3,4- methylenedioxyamphetamine	7400	(III) 3,4 cis or trans tetrahydrocannabinol and its optical isomers; and	
T. 3,4-methylenedioxy-methamphetamine(MDMA)	7405	(IV) Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions are covered.	
U. 3,4-methylenedioxy- <i>N</i> -ethylamphetamine (also known as <i>N</i> -ethylalphamethyl-3,4 (methylenedioxy) phenethylamine, <i>N</i> -ethyl MDA,MDE and MDEA)	7404	OO. Ethylamine analog of phencyclidine	7455
V. <i>N</i> -hydroxy-3,4-methylenedioxyamphetamine (also known as <i>N</i> -hydroxyalpha-methyl-3,4 (methylenedioxy) phenethylamine and <i>N</i> -hydroxy MDA)	7402	Some trade or other names: <i>N</i> -ethyl-1- phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, <i>N</i> -(1-phenylcyclohexyl)-ethylamine, cyclohexamine, PCE;	
W. 3,4,5- trimethoxyamphetamine	7390	PP. Pyrrolidine analog of phencyclidine	7458
X. 5-MeO-DMT or 5-methoxy- <i>N, N</i> -dimethyltryptamine	7431	Some trade or other names: 1-(1-phenylcyclohexyl)- pyrrolidine PCPy, PHP;	
Y. Alpha-methyltryptamine	7432	QQ. Thiophene analog of phencyclidine	7470
Z. Bufotenine	7433	Some trade or other names: 1-(1-(2-thienyl)- cyclohexyl)-piperidine, 2-thienyl analog of phencyclidine, TPCP, TCP;	
Some trade and other names: 3-(b-Dimethylaminoethyl)- 5-hydroxy-yindole; 3-(2-dimethylaminoethyl)- 5-indolol; <i>N, N</i> -dimethylserotonin; 5-hydroxy- <i>N, N</i> -dimethyltryptamine;mappine;		RR. 1-(1-(2-thienyl)cyclohexyl) pyrrolidine	7473
AA. Diethyltryptamine	7434	Some other names: TCPy.	
		SS. <i>Salvia divinorum</i>	
		TT. Salvinorin A	
		UU. 3-Fluoromethcathinone	1233
		VV. 4-Fluoromethcathinone	1238
		WW. Mephedrone, or 4-methylmethcathinone	1248

XX. Methylenedioxypropylvalerone, MDPV, or (1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone	7535	1-yl)-propan-1-one)	7498
YY. Methylone, or 3,4-Methylenedioxyamphetaminone	7540	LLL. <i>alpha</i> -pyrrolidinopentiophenone (Other names: <i>alpha</i> -PVP; <i>alpha</i> -pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one)	7545
ZZ. Quinolin-8-yl 1-pentyl-1 <i>H</i> indole-3-carboxylate (PB-22; QUPIC)	7222	MMM. Butylone (Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one)	7541
AAA. Quinolin-8-yl 1-(5-fluoropentyl)-1 <i>H</i> -indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22)	7225	NNN. Pentedrone (Other names: <i>alpha</i> -methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-1-one)	1246
BBB. <i>N</i> -(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 <i>H</i> indazole-3-carboxamide (AB-FUBINACA)	7012	OOO. Pentylone (Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one)	7542
CCC. <i>N</i> -(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 <i>H</i> -indazole-3-carboxamide (ADB-PINACA)	7035	PPP. Naphyrone (Other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one)	1258
DDD. (1-pentyl-1 <i>H</i> -indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other names: UR-144, 1-pentyl-3-(2,2,3,3-tetramethylcyclopropyl)indole)	7144	QQQ. <i>alpha</i> -pyrrolidinobutiophenone (Other names: <i>alpha</i> -PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one)	7546
EEE. [1-(5-fluoro-pentyl)-1 <i>H</i> indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (Other names: 5-fluoro-UR-144, 5-F-UR-144, XLR11, 1-(5-fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropyl)indole)	7011	RRR. <i>N</i> -(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 <i>H</i> indazole-3-carboxamide (Other names: AB-CHMINACA)	7031
FFF. <i>N</i> -(1-adamantyl)-1-pentyl-1 <i>H</i> indazole-3-carboxamide (Other names: APINACA, AKB48)	7048	SSS. <i>N</i> -(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1 <i>H</i> indazole-3-carboxamide (Other names: AB-PINACA)	7023
GGG. 2-(4-iodo-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)ethanamine (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)	7538	TTT. [1-(5-fluoropentyl)-1 <i>H</i> indazol-3-yl](naphthalen-1-yl)methanone (Other names: THJ-2201)	7024
HHH. 2-(4-chloro-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)ethanamine (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82)	7537	UUU. <i>N</i> -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 <i>H</i> indazole-3-carboxamide (Other names: MAB-CHMINACA; ADB-CHMINACA)	7032
III. 2-(4-bromo-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)ethanamine (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)	7536	VVV. methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-carboxamido)-3,3-dimethylbutanoate (Other names: 5F-ADB; 5F-MDMB-PINACA)	7034
JJJ. 4-methyl- <i>N</i> -ethylcathinone (Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one)	1249	WWW. methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-carboxamido)-3-methylbutanoate (Other names: 5F-AMB)	7033
KKK. 4-methyl- <i>alpha</i> -pyrrolidinopropiophenone, (Other names: 4-MePPP; MePPP; 4-methyl- <i>alpha</i> -pyrrolidinopropiophenone; 1-(4-methylphenyl)-2-(pyrrolidin-		XXX. <i>N</i> -(adamantan-1-yl)-1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-carboxamide (Other names: 5F-APINACA, 5F-AKB48)	7049

YYY. *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide
(Other names:
ADB-FUBINACA) **7010**

ZZZ. methyl 2-(1-(cyclohexylmethyl)-1*H*indole-3-carboxamido)-3,3-dimethylbutanoate
(Other names:
MDMB-CHMICA,
MMB-CHMINACA) **7042**

AAAA. methyl 2-(1-(4-fluorobenzyl)-1*H*indazole-3-carboxamido)-3,3-dimethylbutanoate
(Other names:
MDMB-FUBINACA) **7020**

BBBB. methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamido)-3-methylbutanoate
(Other names:
FUB-AMB, MMB-FUBINACA, AMB-FUBINACA) **(7021)**

[UU]/CCCC. Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(I) Any compound structurally derived from 3-(1-naphthoyl)indole or 1*H*indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(*N*-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Including, but not limited to:

- (a) AM2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole **7201**
- (b) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole
- (c) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole
- (d) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole **7118**
- (e) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole **7019**
- (f) JWH-073, or 1-butyl-3-(1-naphthoyl)indole **7173**
- (g) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole **7081**
- (h) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
- (i) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole **7122**
- (j) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole
- (k) JWH-200, or 1-(2-(4-

- (morpholinyl)ethyl)-3-(1-naphthoyl)indole **7200**
- (l) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole
- (m) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole **7398**

(II) Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(*N*-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent;

(III) Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(*N*-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent;

(IV) Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(*N*-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Including, but not limited to:

- (a) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole
- (b) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole **7203**
- (c) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole **6250**
- (d) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole
- (e) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole **7008**

(V) Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(*N*-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent. Including, but not limited to:

(a) CP 47,497 & homologues, or 2-[(1*R*,3*S*)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol, where side chain n=5, and homologues where side chain n=4,6, or 7; **7297, 7298**

(VI) Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(*N*-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Including, but not limited to:

- (a) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole **7694**
- (b) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR-19 and RCS-4) **7104**

(VII) CP 50,556-1, or [(6*S*,6*aR*,9*R*,10*aR*)-9-hydroxy-6-methyl-3-[(2*R*)-5-phenylpentan-2-yl]oxy-5,6,6*a*,7,8,9,10,10*a*-octahydrophenanthridin-1-yl] acetate

(VIII) HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyl octan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (IX) HU-211, or Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

(X) Dimethylheptylpyran, or DMHP

5. Depressants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

A. Gamma-hydroxybutyric acid and other names GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutonic acid; sodium oxybate; sodium oxybutyrate; 2010

B. Mecloqualone 2572

C. Methaqualone 2565

6. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

A. Aminorex 1585

Some trade or other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5-phenyl-2-oxazolamine;

B. *N*-benzylpiperazine (some other names: BZP, 1-benzylpiperzaine) 7493

C. Cathinone (Some trade or other names: 2-amino-1-phenyl-1-propanone, alphaaminopropiophenone, 2-aminopropiophenone and norephedrone) 1235

D. Fenethylamine 1503

[E. 3-Fluoromethcathinone 1233

F. 4-Fluoromethcathinone 1238

G. Mephedrone, or 4-methylmethcathinone 1248]

[H/E. Methcathinone 1237

Some trade or other names: 2-(methylamino)- propiophenone; alpha-(methylamino) propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-*N*-methylaminopropiophenone; monomethylpropion; ephedrone; *N*-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and URI 432;

[I/F. 4-methoxymethcathinone

[J/G. cis-4-methylaminorex (cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine) 1590

[K. Methylenedioxypropylvalerone, MDPV, or (1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone 7535

L. Methylone, or 3,4-Methylenedioxymethcathinone 7540]

[M/H. 4-Methyl-alpha-pyrrolidinobutophenone, or MPBP

[N/I. N-ethylamphetamine 1475

[O/J. N,N-dimethylamphetamine 1480

(some other names: *N,N*-alpha-trimethylbenzeneethanamine; *N,N*-alphatrimethylphenethylamine)

[P. Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) 7222

Q. Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-

carboxylate (5-fluoro-PB-22; 5F-PB-22) 7225

R. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) 7012

S. N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) 7035]

7. A temporary listing of substances subject to emergency scheduling under federal law shall include any material, compound, mixture or preparation which contains any quantity of the following substances:

[A. (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: UR-144, 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole) 7144

B. [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-UR-144, 5-F-UR-144, XLR11, 1-(5-fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole) 7011

C. N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomer (Other names: APINACA, AKB48) 7048

D. 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) 7538

E. 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) 7537

F. 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) 7536

G. 4-methyl-N-ethylcathinone, its optical, positional, and geometric isomers, salts, and

salts of isomers (Other names: 4-MEC; 2-(ethylamino)-1-(4- methylphenyl)propan-1-one)	1249	AB-PINACA)	7023
H. 4-methyl-alpha-pyrrolidinopropiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-MePPP; MePPP; 4-methyl- alpha-pyrrolidinopropiophenone; 1- (4-methylphenyl)-2-(pyrrolidin- 1-yl)-propan-1-one)	7498	Q. [1-(5-fluoropentyl)-1Hindazol- 3-yl](naphthalen- 1-yl)methanone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: THJ-2201)	7024
I. alphapyrrolidinopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: alpha-PVP; alpha- pyrrolidinovalesterophenone; 1-phenyl-2-(pyrrolidin-1- yl)pentan-1-one)	7545	R. N-[1-[2-hydroxy-2-(thiophen- 2-yl) ethyl]piperidin-4-yl]- N-phenylpropionamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: beta-hydroxythiofentanyl)	9836]
J. Butylone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: bk- MBDB; 1-(1,3-benzodioxol-5- yl)-2-(methylamino)butan-1- one)	7541	[S]A. N-(1-phenethylpiperidin-4- yl)-N-phenylacetamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: acetyl fentanyl)	9821
K. Pentedrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: alpha- methylaminovalesterophenone; 2-(methylamino)-1- phenylpentan-1-one)	1246	[T. N-(1-amino-3,3-dimethyl- 1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1Hindazole- 3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: MAB-CHMINACA; ADB-CHMINACA)	7032
L. Pentylone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: bk- MBDP; 1-(1,3-benzodioxol- 5-yl)-2-(methylamino)pentan- 1-one)	7542	U. methyl 2-(1-(5- fluoropentyl)-1H-indazole-3- carboxamido)-3,3- dimethylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5F-ADB; 5F-MDMB- PINACA)	(7034)
M. Naphyrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: naphthylpyrovalerone; 1- (naphthalen-2-yl)-2- (pyrrolidin-1-yl)pentan-1- one)	1258	V. methyl 2-(1-(5- fluoropentyl)-1H-indazole-3- carboxamido)-3- methylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5F- AMB)	(7033)
N. alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: alpha-PBP; 1-phenyl-2-(pyrrolidin- 1-yl)butan-1-one)	7546	W. N-(adamantan-1-yl)-1-(5- fluoropentyl)-1H-indazole- 3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5F- APINACA, 5F-AKB48)	(7049)
O. N-(1-amino-3-methyl-1- oxobutan-2-yl)-1- (cyclohexylmethyl)-1Hindazole- 3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: AB-CHMINACA)	7031	X. N-(1-amino-3,3-dimethyl- 1-oxobutan-2-yl)-1-(4- fluorobenzyl)-1H-indazole-3- carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: ADB-FUBINACA)	(7010)
P. N-(1-amino-3-methyl-1- oxobutan-2-yl)-1-pentyl-1Hindazole- 3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:		Y. methyl 2-(1- (cyclohexylmethyl)-1Hindole- 3-carboxamido)-3,3- dimethylbutanoate, its optical, positional, and geometric	

- isomers, salts and salts of isomers (Other names: MDMB-CHMICA, MMB-CHMINACA)* (7042)
- Z. *methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: MDMB-FUBINACA)* (7020)
- AA. *N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other names: orthofluorofentanyl, 2-fluorofentanyl)* (9816)
- BB. *2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: methoxyacetyl fentanyl)* (9825)
- CC. *methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: FUB-AMB, MMB-FUBINACA, AMB-FUBINACA)* (7021)
- DD. *N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: cyclopropyl fentanyl)* (9845)]
- [EE]B. *N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: valeryl fentanyl)* [(9804)]9840
- [FF. *N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: para-fluorobutyryl fentanyl)* (9823)]
- [GG]C. *N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: para-methoxybutyryl fentanyl)* (9837)
- [HH]D. *N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: para-chloroisobutyryl fentanyl)* (9826)
- [[I]E. *N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: isobutyryl fentanyl)* (9827)
- [JJ]F. *N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: cyclopentyl fentanyl)* (9847)
- [KK]G. *Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers.* 9850
- (I) Fentanyl-related substance means any substance not otherwise listed under another Administration Controlled Substance Code Number, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act 21 U.S.C. 355, that is structurally related to fentanyl by one (1) or more of the following modifications:
- (a) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;
- (b) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro groups;
- (c) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;
- (d) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; and/or
- (e) Replacement of the *N*-propionyl group by another acyl group.
- [LL]H. *Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: NM2201; CBL2201)* (7221)
- [MM]I. *N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5F-AB-PINACA)* (7025)
- [NN]J. *1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-CN-CUMYLBUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL-4CNBINACA; SGT-78)* (7089)
- [OO]K. *methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate, its*

- optical, positional, and geometric isomers, salts and salts of isomers (Other names: MMB-CHMICA, AMB-CHMICA) (7044)
- [PP]L. 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*pyrrolo[2,3-*b*]pyridine-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5F-CUMYL-P7AICA) (7085)
- [QQ]M. *N*-Ethylpentylone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: ephylone, 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one) (7543)
- N. ethyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (trivial name: 5F-EDMB-PINACA) 7036
- O. methyl 2-(1-(5-fluoropentyl)-1*H*-indole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (trivial name: 5F-MDMB-PICA) 7041
- P. *N*-(adamantan-1-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (trivial names: FUB-AKB48; FUB-APINACA; AKB48 *N*-(4-FLUOROBENZYL)) 7047
- Q. 1-(5-fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (trivial names: 5F-CUMYL-PINACA; SGT-25) 7083
- R. (1-(4-fluorobenzyl)-1*H*-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone, its optical, positional, and geometric isomers, salts and salts of isomers (trivial name: FUB-144) 7014
- S. *N*-Ethylhexedrone, its optical, positional, and geometric isomers, salts and salts of isomers (Other name: 2-(ethylamino)-1-phenylhexan-1-one) 7246
- T. *alpha*-Pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: -PHP; *alpha*-pyrrolidinohexiophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one) 7544
- U. 4-Methyl-*alpha*-ethylaminopentiphenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one) 7245
- V. 4'-Methyl-*alpha*-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: MPHP; 4'-methyl-*alpha*-

- pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one) 7446
- W. *alpha*-Pyrrolidinoheptaphenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one) 7548
- X. 4'-Chloro-*alpha*-pyrrolidinovalerophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-chloro-*alpha*-PVP; 4'-chloro-*alpha*-pyrrolidinopentiphenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one) 7443
- Y. *N,N*-diethyl-2-(2-(4 isopropoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other names: isotonitazene; *N,N*-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1*H*-benzimidazole-1-ethanamine) 9614

8. Khat, to include all parts of the plant presently classified botanically as *catha edulis*, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts. 7032

(B) Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Controlled Substances Code Number set forth opposite it.

1. Substances, vegetable origin, or chemical synthesis. Unless specifically excepted or unless listed in another schedule, Schedule II shall include any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:

A. Opium and opiate; and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone and their respective salts, but including the following:

- | | |
|-----------------------------|------|
| (I) Raw opium | 9600 |
| (II) Opium extracts | 9610 |
| (III) Opium fluid | 9620 |
| (IV) Powdered opium | 9639 |
| (V) Granulated opium | 9640 |
| (VI) Tincture of opium | 9630 |
| (VII) Codeine | 9050 |
| (VIII) Dihydroetorphine | 9334 |
| (IX) Ethylmorphine | 9190 |
| (X) Etorphine hydrochloride | 9059 |
| (XI) Hydrocodone | 9193 |
| (XII) Hydromorphone | 9150 |
| (XIII) Metopon | 9260 |
| (XIV) Morphine | 9300 |
| (XV) Oripavine | 9330 |
| (XVI) Oxycodone | 9143 |
| (XVII) Oxymorphone | 9652 |
| (XVIII) Thebaine | 9333 |

B. Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in subparagraph (1)(B)1.A. of this rule shall be included in Schedule II, except that these substances shall not include the isoquinoline alkaloids of opium;

C. Opium poppy and poppy straw	9650	optical isomers, and salts of its optical isomers	1100
D. Coca leaves (9040) and any salt, compound, derivative, or preparation of coca leaves (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives, and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include:		B. Lisdexamfetamine, its salts, isomers, and salts of its isomers	1205
(I) Decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; or		C. Methamphetamine, its salts, isomers, and salts of its isomers	1105
(II) Ioflupane;		D. Phenmetrazine and its salts	1631
E. Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy)	9670	E. Methylphenidate	1724
2. Opiates. Unless specifically excepted or unless in another schedule any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan, and levopropoxyphene excepted:		4. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:	
A. Alfentanil	9737	A. Amobarbital	2125
B. Alphaprodine	9010	B. Glutethimide	2550
C. Anileridine	9020	C. Pentobarbital	2270
D. Bezitramide	9800	D. Phencyclidine	7471
E. Bulk Dextropropoxyphene (Non-dosage Forms)	9273	E. Secobarbital	2315
F. Carfentanil	9743	5. Hallucinogenic substances:	
G. Dihydrocodeine	9120	A. Nabilone	7379
H. Diphenoxylate	9170	Another name for nabilone: (\pm)trans-3-(1, 1-dimethylheptyl)-6, 6a,7,8,10,10a-hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo(b,d)pyran-9-one.	
I. Fentanyl	9801	B. Dronabinol [(-)-delta-9-trans tetrahydrocannabinol] in an oral solution in a drug product approved for marketing by the United States Food and Drug Administration.	(7365)
J. Isomethadone	9226	6. Immediate precursors. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:	
K. Levo-alphaacetylmethadol	[9220]	A. Immediate precursor to amphetamine and methamphetamine:	
Some other names: levo-alphaacetylmethadol, levomethadyl acetate, LAAM	9648	(I) Phenylacetone	8501
L. Levomethorphan	9210	Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone;	
M. Levorphanol	9220	B. Immediate precursors to phencyclidine (PCP):	
N. Metazocine	9240	(I) 1-phenylcyclohexylamine	7460
O. Methadone	9250	(II) 1-piperidinocyclohexane carbonitrile (PCC)	8603
P. Methadone-Intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane	9254	C. Immediate precursor to fentanyl:	
Q. Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid	9802	(I) 4-anilino-N-phenethyl-4-piperidine (ANPP)	8333
R. Pethidine (Meperidine)	9230	(II) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl)	8366
S. Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine	9232	7. Any material, compound, mixture, or preparation which contains any quantity of the following alkyl nitrites:	
T. Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate	9233	A. Amyl nitrite;	
U. Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid	9234	B. Butyl nitrite.	
V. Phenazocine	9715	(C) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.	
W. Piminodine	9730	1. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:	
X. Racemethorphan	9732	A. Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August	
Y. Racemorphan	9733		
Z. Remifentanil	9739		
AA. Sufentanil	9740		
BB. Tapentadol	9780		
CC. Thiafentanil	9729		

25, 1971, as excepted compounds under section 308.32 and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances

- B. Benzphetamine 1228
- C. Chlorphentermine 1645
- D. Clortermine 1647
- E. Phendimetrazine 1615

2. Depressants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

- A. Any compound, mixture, or preparation containing:
 - (I) Amobarbital 2126
 - (II) Secobarbital 2316
 - (III) Pentobarbital 2271

or any salt thereof and one (1) or more other active medicinal ingredients which are not listed in any schedule;

- B. Any suppository dosage form containing:
 - (I) Amobarbital 2126
 - (II) Secobarbital 2316
 - (III) Pentobarbital 2271

or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;

C. Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof

- D. Chlorhexadol 2510
- E. Embutramide 2020

F. Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomer, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act;

- G. Ketamine, its salts, isomer, and salts of isomers (some other names for ketamine: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone) 7285

H. Lysergic acid 7300

I. Lysergic acid amide 7310

J. Methyprylon 2575

K. Perampanel, and its salts, isomers, and salts of isomers 2261

L. Sulfondiethylmethane 2600

M. Sulfonethylmethane 2605

N. Sulfonmethane 2610

O. Tiletamine and zolazepam or any salt thereof 7295

Some trade or other names for a tiletaminezolazepam combination product: Telazol. Some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e)(1,4)-diazepin-7(1H)-one, flupyrazapon.

3. Nalorphine 9400

4. Narcotics drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof:

A. Not more than 1.8 grams of codeine per one hundred milliliters (100 mL) or not more than ninety milligrams (90 mg) per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium 9803

B. Not more than 1.8 grams of codeine per one hundred milliliters (100 mL) or not more than ninety milligrams (90 mg) per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts 9804

C. Not more than 1.8 grams of dihydrocodeine per one hun-

dred milliliters (100 mL) or not more than ninety milligrams (90 mg) per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts 9807

D. Not more than three hundred milligrams (300 mg) of ethylmorphine per one hundred milliliters (100 mL) or not more than fifteen milligrams (15 mg) per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts 9808

E. Not more than five hundred milligrams (500 mg) of opium per one hundred milliliters (100 mL) or per one hundred grams (100 g) or not more than twenty-five milligrams (25 mg) per dosage unit, with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts 9809

F. Not more than fifty milligrams (50 mg) of morphine per one hundred milliliters (100 mL) or per one hundred grams (100 g), with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts 9810

5. Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:

A. Buprenorphine 9064

6. Anabolic steroids. Unless specially excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation. DEA has assigned code 4000 for all anabolic steroids. Anabolic steroids. Any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for that administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subdivision. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, and ethers:

A. 3β,17β-dihydroxy-5α-androstane

B. 3α,17β-dihydroxy-5α-androstane

C. 5α-androstan-3,17-dione

D. 1-androstenediol (3β,17β-dihydroxy- 5α-androst-1-ene)

E. 1-androstenediol (3α,17β-dihydroxy- 5α-androst-1-ene)

F. 4-androstenediol (3β,17β-dihydroxy- androst-4-ene)

G. 5-androstenediol (3β,17β-dihydroxy- androst-5-ene)

H. 1-androstenedione ([5α]-androst- 1-en-3,17-dione)

I. 4-androstenedione (androst-4-en- 3,17-dione)

J. 5-androstenedione (androst-5-en- 3,17-dione)

K. Bolasterone (7α,17α-dimethyl- 17β-hydroxyandrost-4-en-3-one)

L. Boldenone (17β-hydroxyandrost- 1,4,-diene-3-one)

M. Boldione (androstra-1,4-diene- 3,17-dione)

N. Calusterone (7β,17α-dimethyl-17 β-hydroxyandrost-4-en-3-one)

O. Clostebol (4-chloro-17β-hydroxyandrost- 4-en-3-one)

P. Dehydrochloromethyltestosterone (4-chloro-17β-hydroxy-17α-methyl-androst- 1,4-dien-3-one)

Q. Desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol) (a.k.a. madol)

[R. Dihydrotestosterone (4-Dihydrotestosterone) (s) 4-dihydrotestosterone (17β-hydroxy-androstan-3-one)]

R. Δ1-dihydrotestosterone (a.k.a.'1-testosterone') (17β-hydroxy-5α-androst-1-en-3-one)

S. 4-dihydrotestosterone (17β-hydroxy-androstan-3-one)

[S/T. Drostanolone(17β-hydroxy-2α-methyl-5α-androstan-3-one)

/TU. Ethylestrenol(17 α -ethyl-17 β -hydroxyestr-4-ene)
/UV. Fluoxymesterone(9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrost-4-en-3-one)
/VW. Formebolone (Formebolone) (2- formyl-17 α -methyl-11 α ,17 β -dihydroxyandrost- 1,4-dien-3-one)
/WX. Furazabol (17 α -methyl-17 β -hydroxyandrostano[2,3-c]-furan)
/XY. 13 β -ethyl-17 β -hydroxygon-4-en-3-one
/YZ. 4-hydroxytestosterone (4,17 β -dihydroxy- androst-4-en-3-one)
/ZAA. 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one)
/AAB. Mestanolone (17 α -methyl-17 β -hydroxy-5 α -androstan-3-one)
/BBC. Mesterolone(1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one)
/CCD. Methandienone(17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one)
/DDE. Methandriol (17 α -methyl- 3 β ,17 β -dihydroxyandrost-5-ene)
/EEF. Methasterone (2 α ,17 α -dimethyl-5 α -androstan-17 β -ol-3-one)
/FFG. Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one)
/GGH. 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstane
/HHI. 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane
/IJJ. 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene
/JJK. 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4- en-3-one)
/KKL. Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one)
/LLM. Methyltrienolone (17 α -methyl- 17 β -hydroxyestra-4,9,11-trien-3-one)
/MMN. Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one)
/NNO. Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one)
/OOP. 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one) (a.k.a. 17- α -methyl-1-testosterone)
/PPQ. Nandrolone (17 β -hydroxyestr-4-ene-3-one)
/QQR. 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene)
/RRS. 19-nor-4-andro stenediol (3 α ,17 β -dihydroxyestr-4-ene)
/SST. 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione)
/TTU. 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene)
/UVV. 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene)
/VWW. 19-nor-4-androstenedione (estr-4-en-3,17-dione)
/WXX. 19-nor-5-androstenedione (estr-5-en-3,17-dione)
/XYY. Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one)
/YYZ. Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one)
/ZZAAA. Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one)
/AABBB. Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one)
/BBBCCC. Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one)
/CCCDDD. Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one)
/DDEEEE. Oxymetholone (17 α -methyl-2-hydroxymethyl-ene-17 β -hydroxy-[5 α]-androstan-3-one)
/EEEFF. Prostanazol (17 β -hydroxy-5 α -androstano[3,2-

c]pyrazole)
/FFFGGG. Stanolone (Δ 1-dihydrotestosterone (a.k.a. 1-testosterone)(17 β -hydroxy-5 α -androst-1-en-3-one))
/GGGHHH. Stanozolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole)
/HHHIII. Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one)
/IIJJJJ. Testolactone(13-hydroxy-3-oxo-13,17-secoandrost-1,4-dien-17-oiic acid lactone)
/JJJKKK. Testosterone(17 β -hydroxyandrost-4-en-3-one);
/KKKLLL. Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9, 11-trien-3-one)
/LLLMMM. Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one)
/MMMNNN. Any salt, ester, or isomer of a drug or substance described or listed in this subparagraph, if that salt, ester, or isomer promotes muscle growth except an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the secretary of Health and Human Services for that administration.
7. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product 7369
(Some other names for dronabinol: (6aRtrans)- 6a,7,8,10a-tetrahydro-6.6.9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol, or (-) -delta-9-(trans)-tetrahydrocannabinol.)
(D) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.
1. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof:
A. Not more than one milligram (1 mg) of difenoxin (DEA Drug Code No. 9168) and not less than twenty-five micrograms (25 mcg) of atropine sulfate per dosage unit 9167
B. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane) 9278
C. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, opticaland geometric isomers, and salts of these isomers (including tramadol) 9752
D. Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one (1) or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
(I) Not more than two hundred milligrams (200 mg) of codeine per one hundred milliliters (100 mL) or per one hundred grams (100 g);
(II) Not more than one hundred milligrams (100 mg) of dihydrocodeine per one hundred milliliters (100 mL) or per one hundred grams (100 g); or
(III) Not more than one hundred milligrams (100 mg) of ethylmorphine per one hundred milliliters (100 mL) or per one hundred grams (100 g).
2. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
A. Alfaxalone 2731
B. Alprazolam 2882
C. Barbitol 2145

D. Brexanolone	2400
/D/E. Bromazepam	2748
/E/F. Camazepam	2749
/F/G. Carisoprodol	8192
/G/H. Chloral betaine	2460
/H/I. Chloral hydrate	2465
/I/J. Chlordiazepoxide	2744
/J/K. Clobazam	2751
/K/L. Clonazepam	2737
/L/M. Clorazepate	2768
/M/N. Clotiazepam	2752
/N/O. Cloxazolam	2753
/O/P. Delorazepam	2754
/P/Q. Diazepam	2765
/Q/R. Dichloralphenazone	2467
/R/S. Estazolam	2756
/S/T. Ethchlorvynol	2540
/T/U. Ethinamate	2545
/U/V. Ethyl loflazepam	2758
/V/W. Fludiazepam	2759
/W/X. Flunitrazepam	2763
/X/Y. Flurazepam	2767
/Y/Z. Fospropofol	2138
/Z/AA. Halazepam	2762
/AA/BB. Haloxazolam	2771
/BB/CC. Ketazolam	2772
DD. Lemborexant	2245
/CC/EE. Loprazolam	2773
/DD/FF. Lorazepam	2885
/EE/GG. Lormetazepam	2774
/FF/HH. Mebutamate	2800
/GG/II. Medazepam	2836
/HH/JJ. Meprobamate	2820
/II/KK. Methohexital	2264
/JJ/LL. Methylphenobarbital (Mephobarbital)	2250
/KK/MM. Midazolam	2884
/LL/NN. Nimetazepam	2837
/MM/OO. Nitrazepam	2834
/NN/PP. Nordiazepam	2838
/OO/QQ. Oxazepam	2835
/PP/RR. Oxazolam	2839
/QQ/SS. Paraldehyde	2585
/RR/TT. Petrichloral	2591
/SS/UU. Phenobarbital	2285
/TT/VV. Pinazepam	2883
/UU/WW. Prazepam	2764
/VV/XX. Quazepam	2881
/WW/YY. Suvorexant	2223
/XX/ZZ. Temazepam	2925
/YY/AAA. Tetrazepam	2886
/ZZ/BBB. Triazolam	2887
/AAA/CCC. Zaleplon	2781
/BBB/DDD. Zolpidem	2783
/CCC/EEE. Zopiclone	2784

3. Fenfluramine. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

A. Fenfluramine 1670

4. Lorcaserin. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

A. Lorcaserin 1625

5. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation

which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

A. Cathine ((+)- norpseudoephedrine)	1230
B. Diethylpropion	1610
C. Fencamfamin	1760
D. Fenproporex	1575
E. Mazindol	1605
F. Mefenorex	1580
G. Modafinil	1680
H. Pemoline (including organometallic complexes and chelates thereof)	1530
I. Phentermine	1640
J. Pipradrol	1750
K. Sibutramine	1675

L. Solriamfetol (2-amino-3-phenylpropyl carbamate; benzenepropanol, beta-amino-, carbamate (ester)) 1650

/L/M. SPA (-)-1-dimethylamino-1,2-diphenylethane 1635

6. Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts:

A. Pentazocine	9709
B. Butorphanol (including its optical isomers)	9720
C. Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl]-2,6-dimethylphenyl]-1-oxopropyl] [(1S)-1-(4-phenyl-1 H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers	9725

7. Ephedrine. Any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system including their salts, isomers, and salts of isomers:

A. Ephedrine or its salts, optical isomers, or salts of optical isomers as the only active medicinal ingredient or contains ephedrine or its salts, optical isomers, or salts of optical isomers and therapeutically insignificant quantities of another active medicinal ingredient.

(E) Schedule V shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this subsection.

1. Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as follows, which shall include one (1) or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

A. Not more than two hundred milligrams (200 mg) of codeine per one hundred milliliters (100 mL) or per one hundred grams (100 g);

B. Not more than one hundred milligrams (100 mg) of dihydrocodeine per one hundred milliliters (100 mL) or per one hundred grams (100 g);

C. Not more than one hundred milligrams (100 mg) of ethylmorphine per one hundred milliliters (100 mL) or per one hundred grams (100 g);

D. Not more than two and five-tenths milligrams (2.5 mg) of diphenoxylate and not less than twenty-five micrograms (25 mcg) of atropine sulfate per dosage unit;

E. Not more than one hundred milligrams (100 mg) of opium per one hundred milliliters (100 mL) or per one hundred grams (100 g); and

F. Not more than five-tenths milligram (0.5 mg) of difenoxin (DEA Drug Code No. 9168) and not less than twenty-five micrograms (25 mcg) of atropine sulfate per dosage unit.

2. Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system including its salts, isomers, and salts of isomers:

A. Pyrovalerone 1485

3. Any compound, mixture, or preparation containing any detectable quantity of pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound, mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical isomers, or salts of optical isomers if the drug preparations are starch-based solid dose forms, if such preparations are sold over the counter without a prescription. The following drug preparations containing ephedrine and pseudoephedrine are not scheduled controlled substances:

A. Drug preparations in liquid form;

B. Drug preparations that require a prescription in order to be dispensed.

4. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:

A. Ezogabine [N-[2-amino-4(4-fluorobenzylamino)-phenyl]-carbamate ethyl ester] 2779

B. Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide] 2746

C. Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid] 2782

D. Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; UCB-34714; Briviact) 2710

E. Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl)-benzamide] 2790

F. Cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester 2720

[5. Approved cannabidiol drugs.

A. A drug product in finished dosage formulation that has been approved by the U.S. Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzene-diol) derived from cannabis and no more than one tenth percent (0.1%) (w/w) residual tetrahydro cannabinoids 7367]

AUTHORITY: sections 195.015 and 195.195, RSMo Supp. [2017] 2020. Material found in this rule previously filed as 19 CSR 30-1.010. Original rule filed April 14, 2000, effective Nov. 30, 2000. For intervening history, please consult the Code of State Regulations. Emergency amendment filed Oct. 30, 2020, effective Nov. 16, 2020,

expires May 14, 2021. A proposed amendment covering this same material is published in this issue of the Missouri Register

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the emergency is effective.

Title 19—DEPARTMENT OF HEALTH AND SENIOR SERVICES
Division 30—Division of Regulation and Licensure
Chapter 1—Controlled Substances

EMERGENCY AMENDMENT

19 CSR 30-1.074 Dispensing Without a Prescription. The department is amending subsections (3)(B), (3)(C), and (3)(L).

PURPOSE: This emergency amendment updates the requirements for the sale, dispensation, or distribution of methamphetamine precursor products to be consistent with section 195.417, RSMo.

EMERGENCY STATEMENT: Section 195.417, RSMo was amended through SS SCS HCS HB 1682 (2020). This statutory amendment reduced that amount of methamphetamine precursor products that pharmacy may dispense within a thirty- (30-) day period from nine (9) grams to seven and two-tenths (7.2) grams. It also placed limit on the amount of methamphetamine precursor products a pharmacy may dispense to an individual or that an individual may otherwise receive within a twelve- (12-) month period to forty-three and two-tenths (43.2) grams. This emergency amendment will ensure that Missouri's controlled substance regulations contain these same limits rather than purchase limits that exceed those now allowed by statute. Limiting the amount of methamphetamine precursor products that may be dispensed to an individual (with or without a prescription) in a given period of time helps ensure that those individuals are purchasing for lawful reasons and not with the intent of using the products to manufacture methamphetamine. There are currently one thousand three hundred sixty-nine (1,369) pharmacies registered with the Department of Health and Senior Services Bureau of Narcotics and Dangerous Drugs. Not all of these pharmacies dispense methamphetamine precursor products, but for those that do it is important that the regulations they agree to follow as registrants are consistent with state law, not only to prevent confusion, but to ensure the Bureau can discipline a registrant for violating state law if needed. The scope of this emergency amendment is limited to the circumstances creating the emergency and complies with the protections extended in the Missouri and United States Constitutions. The Department of Health and Senior Services believes this emergency amendment is fair to all interested persons and parties under the circumstances. A proposed amendment, which covers this same material, is published in this issue of the Missouri Register. This emergency amendment was filed October 30, 2020, becomes effective November 16, 2020, and expires May 14, 2021.

(3) Methamphetamine precursor products may be sold, dispensed, distributed, or otherwise provided only as follows:

(B) Dispensers of methamphetamine precursor products shall exercise reasonable care in assuring that the purchaser has not exceeded the three and six-tenths (3.6)-gram limit per day or the [nine (9)] seven and two-tenths (7.2)-gram limit per thirty (30)-day period. **Within any twelve-month period, no person shall sell, dispense, or otherwise provide the same individual, and no person**

shall purchase, receive or otherwise acquire more than forty-three and two-tenths (43.2)-grams, without regard to the number of transactions;

(C) Dispensers shall utilize the real-time electronic pseudoephedrine tracking system established and maintained by the Missouri Department of Health and Senior Services (DHSS). No prescription shall be required for the sale or dispensing of these drug products; however, prescribers and patients may voluntarily choose to use a prescription by voluntary choice when deemed appropriate by the prescriber in the course of his or her professional practice;

(L) Denials of Sales and Dispensings.

1. Except as provided in subsection (D) of this section, if an individual attempts to purchase a methamphetamine precursor product in violation of the three and six-tenths (3.6) gram per day or [nine (9)] seven and two-tenths (7.2) gram per month quantity restrictions or age restriction established by sections 195.017 and 195.417, RSMo, the dispenser shall refuse to make the sale. The purchaser must be at least eighteen (18) years of age.

2. Sales of methamphetamine precursor products shall be denied to purchasers who are not able to produce a valid government issued identification card with the required information displayed on it.

3. In the event that the dispenser perceives that refusal of the purchase may place him or her in imminent physical harm, then the dispenser may use the database safety override function to proceed with the transaction, provided that—

A. When jeopardy is no longer perceived, the dispenser shall immediately contact local law enforcement to report the purchase; and

B. The dispenser shall document in their manual log, the circumstance, the individual contacted at the local law enforcement agency, and the date and time of that contact;

AUTHORITY: sections 195.017 and 195.417, RSMo Supp. [2010] 2020, and sections 195.030, 195.050, and 195.195, RSMo [2000] 2016. Original rule filed April 14, 2000, effective Nov. 30, 2000. For intervening history, please consult the Code of State Regulations. Emergency amendment filed Oct. 30, 2020, effective Nov. 16, 2020, expires May 14, 2021. A proposed amendment covering this same material is published in this issue of the Missouri Register.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

Title 20—DEPARTMENT OF COMMERCE AND INSURANCE

Division 2220—State Board of Pharmacy Chapter 5—Drug Distributor

EMERGENCY AMENDMENT

20 CSR 2220-5.020 Drug Distributor Licensing Requirements.

The Board of Pharmacy is amending subsection (1)(B).

PURPOSE: This emergency amendment would waive Missouri drug distributor licensure requirements for entities shipping drugs or vaccines to treat or immunize patients during a state or federally declared disaster or emergency, or pursuant to an emergency use authorization issued by the United States Food and Drug Administration for a public health emergency.

EMERGENCY STATEMENT: On January 31, 2020, the U.S.

Department of Health and Human Services (HHS) declared a public health emergency in response to the nationwide COVID-19 pandemic. The Governor of Missouri declared a similar State of Emergency on March 13, 2020, finding that COVID-19 poses a serious health risk for Missouri residents and visitors. HHS is currently collaborating with U.S. drug manufacturers to develop a COVID-19 vaccine/treatment, with anticipated availability as early as November 2020. In response, the Missouri Department of Health and Senior Services (DHSS) has developed a statewide vaccine and drug distribution plan to coordinate shipment of federally authorized drug supplies into Missouri. The statewide distribution/shipment plan includes procedures for intrastate shipments of emergency medication between state/federally authorized first responders/healthcare entities (e.g., hospitals, local public health agencies, physician clinics, mobile/temporary vaccination sites). Under the current rule, a Missouri drug distributor license is required for entities shipping medication pursuant to the emergency plan and declaration. HHS and the United States Centers for Disease Control and Prevention (CDC) have asked all states to remove licensing related barriers that would impede nationwide coordination of medication shipments during the federal emergency. DHSS has made a similar request to the board. Significantly, state/federal authorities have advised drug shipments may need to be coordinated between entities with little or no advance notification. Board processing of a Missouri drug distributor application could delay drug shipments by 4-6 weeks due to current application requirements (e.g., notarization, state inspection, and non-resident independent license verification from other states). In line with the HHS, CDC and DHSS requests, the proposed emergency amendment would exempt entities distributing medication and drug supplies to treat Missouri patients during a state/federal emergency from Missouri's drug distributor licensure requirements. The board has determined this emergency amendment is needed to ensure the availability and prompt distribution of medication to treat/prevent COVID-19 and other medical needs/illnesses during a federal or state emergency. Absent an emergency amendment, Missouri citizens will experience a significant delay in receiving COVID-19 vaccines/medication and related emergency supplies, which will detrimentally impact the public safety, health, and welfare of Missouri citizens. As a result, the Missouri State Board of Pharmacy finds there is an immediate danger to the public health, safety, and/or welfare and a compelling governmental interest that requires this emergency action. The scope of this emergency rule amendment is limited to the circumstances creating the emergency and complies with the protections extended in the Missouri and United States Constitutions. The Missouri State Board of Pharmacy believes this emergency rule is fair to all interested persons and parties under the circumstances. A proposed amendment, which covers the same material, is published in this issue of the Missouri Register. This emergency amendment was filed October 29, 2020, becomes effective November 13, 2020, and expires May 11, 2021.

(1) A "wholesale drug distributor" is defined in section 338.330(3), RSMo. No wholesale drug distributor with physical facilities located in the state of Missouri shall knowingly purchase or receive legend drugs and/or drug related devices from a wholesale drug distributor or pharmacy not licensed or registered by the board. Knowledge of the licensure status of a drug distributor or pharmacy includes, but is not limited to, actual or constructive knowledge. Knowledge of the license status of a drug distributor or pharmacy shall also include, but not be limited to, notification from the board by mail or electronic transmission.

(B) Licensure and/or registration as a wholesale drug distributor is not required for activities described below—

1. The sale, purchase, transfer, or trade of a drug or an offer to sell, purchase, transfer, or trade a drug for emergency administration to an individual patient if a delay in therapy would negatively affect a patient outcome. The amount sold, purchased, transferred, or traded shall not exceed five percent (5%) of the pharmacy's total gross

prescription sales or, if prescriptions are not sold, five percent (5%) of the pharmacy's total drug purchases;

2. The sale, purchase, or trade of blood and blood components intended for transfusion and any other exemptions as provided for in Chapter 338, RSMo;

3. The sale, purchase, transfer, or trade of a drug or an offer to sell, purchase, or trade a drug by a Missouri licensed pharmacy that does not exceed five percent (5%) of the pharmacy's total gross sales. For purposes of this section, total gross sales shall be calculated based on the pharmacy's total annual prescription drug sales or, if prescriptions are not sold, five percent (5%) of the pharmacy's total drug purchases;

4. The sale, purchase, transfer, or trade of a drug or offer to sell, purchase, transfer, or trade a drug among hospitals or by a hospital to a healthcare entity under the same common control or ownership as the hospital. "Common control or ownership" means the power to direct or cause the direction of the management and policies of a person or an organization whether by ownership, stock, voting rights, contract, or otherwise. For purposes of this rule, a "hospital" shall be limited to a hospital as defined by Chapter 197, RSMo, or a hospital operated by the state;

5. The storage or distribution of drugs by a local, state, or federal facility that are received from the Strategic National Stockpile or the state stockpile for the purpose of providing those drugs in an emergency situation as authorized by a state or federal agency;

6. The sale, purchase, or transfer of a drug or vaccine received from or on behalf of a federal, state, or municipal entity for the purpose of treating or immunizing patients during a state or federally declared disaster or emergency;

7. The sale, purchase, or transfer of a drug or vaccine subject to an emergency use authorization issued by the United States Food and Drug Administration for a public health emergency;

[6.]8. The sale, purchase, transfer, or trade of a prescription drug to alleviate a temporary shortage of a prescription drug that is in limited supply or unavailable due to delays in or interruption of supply. Drugs sold, purchased, transferred, or traded pursuant to this section shall only be sold, purchased, transferred, or traded directly from an importer or manufacturer authorized by or registered with the United States Food and Drug Administration (FDA) to import or manufacture the drug that is unavailable or in short supply. In addition, sales, purchases, transfers, or trades shall be limited to the period of shortage and to the drug that is unavailable or in limited supply. Documentation of FDA authorization or registration shall be maintained in the licensee's or recipient's records; and

[7.]9. The sale, purchase, transfer, or trade of a drug between a Missouri licensed pharmacy and a non-resident pharmacy that is located in and licensed by another state or United States territory. The total amount of drug sold, purchased, transferred, or traded by the Missouri-licensed pharmacy pursuant to this subsection shall not exceed five percent (5%) of the pharmacy's total annual prescription drug sales. Missouri pharmacies receiving drugs pursuant to this section from a non-resident pharmacy shall maintain the following records for two (2) years from the date of sale, purchase, transfer, or trade:

A. Proof the non-resident pharmacy holds a current pharmacy license in the state or territory from which the drug is shipped or distributed; and

B. An invoice record which documents the name and address of the non-resident pharmacy, the date of sale, purchase, transfer, or trade, and the name, strength, and quantity of the drug received. The pharmacies shall also comply with all applicable controlled substance requirements.

AUTHORITY: sections [338.340] 338.335 and 338.350, RSMo [2000] 2016, and sections 338.140.1, 338.315, 338.330, 338.333, [338.335] 338.337, and 338.340, RSMo Supp. [2014] 2020. This rule originally filed as 4 CSR 220-5.020. Original rule filed Feb. 4,

1991, effective June 10, 1991. For intervening history, please consult the Code of State Regulations. Emergency amendment filed Oct. 29, 2020, effective Nov. 13, 2020, expires May 11, 2021. A proposed amendment covering this same material is published in this issue of the Missouri Register.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

Title 22—MISSOURI CONSOLIDATED HEALTH CARE PLAN Division 10—Health Care Plan Chapter 2—State Membership

EMERGENCY AMENDMENT

22 CSR 10-2.046 PPO 750 Plan Benefit Provisions and Covered Charges. The Missouri Consolidated Health Care Plan is amending section (5).

PURPOSE: This emergency amendment adds one hundred percent (100%) coverage of virtual visits offered through the vendor's telehealth tool.

EMERGENCY STATEMENT: This emergency amendment must be in place by January 1, 2021, in accordance with the new plan year. Therefore, this emergency amendment is necessary to serve a compelling governmental interest of protecting members (employees, retirees, officers, and their families) enrolled in the Missouri Consolidated Health Care Plan (MCHCP) from the unintended consequences of confusion regarding eligibility or availability of benefits and will allow members to take advantage of opportunities for reduced premiums for more affordable options without which they may forgo coverage. Further, it clarifies member eligibility and responsibility for various types of eligible charges, beginning with the first day of coverage for the new plan year. It may also help ensure that inappropriate claims are not made against the state and help protect the MCHCP and its members from being subjected to unexpected and significant financial liability and/or litigation. It is imperative that this amendment be filed as an emergency amendment to maintain the integrity of the current health care plan. This emergency amendment fulfills the compelling governmental interest of offering access to more convenient and affordable medical services to members as one (1) method of protecting the MCHCP trust fund from more costly expenses. This emergency amendment reflects changes made to the plan by the Missouri Consolidated Health Care Plan Board of Trustees. A proposed amendment, which covers the same material, is published in this issue of the Missouri Register. This emergency amendment complies with the protections extended by the Missouri and United States Constitutions and limits its scope to the circumstances creating the emergency. The MCHCP follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances. This emergency amendment was filed October 26, 2020, becomes effective January 1, 2021, and expires June 29, 2021.

(5) The following services are not subject to deductible, coinsurance, or copayment requirements and will be paid at one hundred percent (100%) when provided by a network provider:

- (D) Four (4) Diabetes Self-Management Education visits; *[and]*
- (E) Sterilization procedure for men~~./~~; **and**
- (F) **Virtual visits offered through the vendor's telehealth tool.**

AUTHORITY: section 103.059, RSMo 2016. Emergency rule filed Oct. 31, 2018, effective Jan. 1, 2019, expired June 29, 2019. Original rule filed Oct. 31, 2018, effective May 30, 2019. Emergency amendment filed Oct. 30, 2019, effective Jan. 1, 2020, expired June 28, 2020. Amended: Filed Oct. 30, 2019, effective May 30, 2020. Emergency amendment filed Oct. 26, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material is published in this issue of the **Missouri Register**.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

**Title 22—MISSOURI CONSOLIDATED
HEALTH CARE PLAN
Division 10—Health Care Plan
Chapter 2—State Membership
EMERGENCY AMENDMENT**

22 CSR 10-2.047 PPO 1250 Plan Benefit Provisions and Covered Charges. The Missouri Consolidated Health Care Plan is amending section (5).

PURPOSE: This emergency amendment adds one hundred percent (100%) coverage of virtual visits offered through the vendor's telehealth tool.

EMERGENCY STATEMENT: This emergency amendment must be in place by January 1, 2021, in accordance with the new plan year. Therefore, this emergency amendment is necessary to serve a compelling governmental interest of protecting members (employees, retirees, officers, and their families) enrolled in the Missouri Consolidated Health Care Plan (MCHCP) from the unintended consequences of confusion regarding eligibility or availability of benefits and will allow members to take advantage of opportunities for reduced premiums for more affordable options without which they may forgo coverage. Further, it clarifies member eligibility and responsibility for various types of eligible charges, beginning with the first day of coverage for the new plan year. It may also help ensure that inappropriate claims are not made against the state and help protect the MCHCP and its members from being subjected to unexpected and significant financial liability and/or litigation. It is imperative that this amendment be filed as an emergency amendment to maintain the integrity of the current health care plan. This emergency amendment fulfills the compelling governmental interest of offering access to more convenient and affordable medical services to members as one (1) method of protecting the MCHCP trust fund from more costly expenses. This emergency amendment reflects changes made to the plan by the Missouri Consolidated Health Care Plan Board of Trustees. A proposed amendment, which covers the same material, is published in this issue of the **Missouri Register**. This emergency amendment complies with the protections extended by the **Missouri and United States Constitutions** and limits its scope to the circumstances creating the emergency. The MCHCP follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances. This emergency amendment was filed October 26, 2020, becomes effective January 1, 2021, and expires June 29, 2021.

(5) The following services are not subject to deductible, coinsurance, or copayment requirements and will be paid at one hundred percent (100%) when provided by a network provider:

- (D) Four (4) Diabetes Self-Management Education visits; *[and]*
- (E) Sterilization procedure for men/.; **and**
- (F) **Virtual visits offered through the vendor's telehealth tool.**

AUTHORITY: section 103.059, RSMo 2016. Emergency rule filed Oct. 31, 2018, effective Jan. 1, 2019, expired June 29, 2019. Original rule filed Oct. 31, 2018, effective May 30, 2019. Emergency amendment filed Oct. 30, 2019, effective Jan. 1, 2020, expired June 28, 2020. Amended: Filed Oct. 30, 2019, effective May 30, 2020. Emergency amendment filed Oct. 26, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material is published in this issue of the **Missouri Register**.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

**Title 22—MISSOURI CONSOLIDATED
HEALTH CARE PLAN
Division 10—Health Care Plan
Chapter 2—State Membership
EMERGENCY AMENDMENT**

22 CSR 10-2.053 Health Savings Account Plan Benefit Provisions and Covered Charges. The Missouri Consolidated Health Care Plan is amending section (3), adding section (10), and renumbering as necessary.

PURPOSE: This emergency amendment revises the out-of-pocket maximum for individual family members and adds one hundred percent (100%) coverage of virtual visits offered through the vendor's telehealth tool.

EMERGENCY STATEMENT: This emergency amendment must be in place by January 1, 2021, in accordance with the new plan year. Therefore, this emergency amendment is necessary to serve a compelling governmental interest of protecting members (employees, retirees, officers, and their families) enrolled in the Missouri Consolidated Health Care Plan (MCHCP) from the unintended consequences of confusion regarding eligibility or availability of benefits and will allow members to take advantage of opportunities for reduced premiums for more affordable options without which they may forgo coverage. Further, it clarifies member eligibility and responsibility for various types of eligible charges, beginning with the first day of coverage for the new plan year. It may also help ensure that inappropriate claims are not made against the state and help protect the MCHCP and its members from being subjected to unexpected and significant financial liability and/or litigation. It is imperative that this amendment be filed as an emergency amendment to maintain the integrity of the current health care plan. This emergency amendment fulfills the compelling governmental interest of offering access to more convenient and affordable medical services to members as one (1) method of protecting the MCHCP trust fund from more costly expenses. This emergency amendment reflects changes made to the plan by the Missouri Consolidated Health Care Plan Board of Trustees. A proposed amendment, which covers the same material, is published in this issue of the **Missouri Register**. This emergency amendment complies with the protections extended by the **Missouri and United States Constitutions** and limits its scope to the circumstances creating the emergency. The MCHCP follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances. This emergency amendment was

filed October 26, 2020, becomes effective January 1, 2021, and expires June 29, 2021.

(3) Out-of-pocket maximum.

(A) The family out-of-pocket maximum applies when two (2) or more family members are covered. The family out-of-pocket maximum must be met before the plan begins to pay one hundred percent (100%) of all covered charges for any covered family member. Out-of-pocket maximums are per calendar year, as follows:

1. Network out-of-pocket maximum for individual—four thousand nine hundred fifty dollars (\$4,950);

2. Network out-of-pocket maximum for family—nine thousand nine hundred dollars (\$9,900). Any individual family member need only incur a maximum of *eight thousand one hundred fifty dollars (\$8,150)* **eight thousand five hundred fifty dollars (\$8,550)** before the plan begins paying one hundred percent (100%) of covered charges for that individual;

3. Non-network out-of-pocket maximum for individual—nine thousand nine hundred dollars (\$9,900); and

4. Non-network out-of-pocket maximum for family—nineteen thousand eight hundred dollars (\$19,800).

(10) Virtual visits offered through the vendor's telehealth tool are covered at one hundred percent (100%).

[(10)](11) Newborn's claims will be subject to deductible and coinsurance.

[(11)](12) Married, active employees who are MCHCP subscribers and have enrolled children may meet only one (1) family deductible and out-of-pocket maximum. Both spouses must enroll in the same medical plan option through the same carrier, and each must provide the other spouse's Social Security number (SSN) and report the other spouse as eligible for coverage when newly hired and during the open enrollment process. In the medical plan vendor and pharmacy benefit manager system, the spouse with children enrolled will be considered the subscriber and the spouse that does not have children enrolled will be considered a dependent. If both spouses have children enrolled the spouse with the higher Social Security number (SSN) will be considered the subscriber. Failure to report an active employee spouse when newly hired and/or during open enrollment will result in a separate deductible and out-of-pocket maximum for both active employees.

[(12)](13) Each subscriber will have access to payment information of the family unit only when authorization is granted by the adult covered dependent(s).

[(13)](14) Expenses toward the deductible and out-of-pocket maximum will be transferred if the member changes non-Medicare medical plans or continues enrollment under another subscriber's non-Medicare medical plan within the same plan year.

[(14)](15) Maximum plan payment—Non-network medical claims that are not otherwise subject to a contractual discount arrangement are processed at one hundred ten percent (110%) of Medicare reimbursement for non-network professional claims and following the claims administrator's standard practice for non-network facility claims. Members may be held liable for the amount of the fee above the allowed amount.

[(15)](16) Any claim must be initially submitted within twelve (12) months following the date of service, unless otherwise specified in the network provider contract. The plan reserves the right to deny claims not timely filed. A provider initiated correction to the originally filed claim must be submitted within the timeframe agreed in the provider contract, but not to exceed three hundred sixty-five (365) days from adjudication of the originally filed claim. Any claims

reprocessed as primary based on action taken by Medicare or Medicaid must be initiated within three (3) years of the claim being incurred.

[(16)](17) For a member who is an inpatient on the last calendar day of a plan year and remains an inpatient into the next plan year, the prior plan year's applicable deductible and/or coinsurance amounts will apply to the in-hospital facility and related ancillary charges until the member is discharged.

[(17)](18) Services performed in a country other than the United States may be covered if the service is included in 22 CSR 10-2.055. Emergency and urgent care services are covered as a network benefit. All other non-emergency services are covered as determined by the claims administrator. If the service is provided by a non-network provider, the member may be required to provide payment to the provider and then file a claim for reimbursement subject to timely filing limits.

[(18)](19) An active employee subscriber does not qualify for the HSA Plan if s/he is claimed as a dependent on another person's tax return or, except for the plans listed in section (20) of this rule, is covered under or enrolled in any other health plan that is not a high deductible health plan, including, but not limited to, the following types of insurance plans or programs:

(A) Medicare (unless Medicare is secondary coverage to MCHCP);

(B) TRICARE;

(C) A health care flexible spending account (FSA), with the exception of participation in the premium-only, limited-purpose health FSA, and dependent care section;

(D) Health reimbursement account (HRA); or

(E) If the member has received medical benefits from The Department of Veterans Affairs (VA) at any time during the previous three (3) months, unless the medical benefits received consist solely of disregarded coverage or preventive care.

[(19)](20) If an active employee subscriber and/or his/her dependent(s) is enrolled in the HSA Plan and becomes ineligible for the HSA Plan during the plan year, the subscriber and/or his/her dependent(s) will be enrolled in the PPO 1250 Plan. The subscriber may enroll in a different non-HSA Plan within thirty-one (31) days of notice from MCHCP.

[(20)](21) A subscriber may qualify for this plan even if s/he is covered by any of the following:

(A) Drug discount card;

(B) Accident insurance;

(C) Disability insurance;

(D) Dental insurance;

(E) Vision insurance; or

(F) Long-term care insurance.

[(21)](22) Health Savings Account (HSA) Contributions.

(A) To receive contributions from MCHCP, the subscriber must be an active employee and HSA eligible as defined in the Internal Revenue Service Publication 969 on the date the contribution is made and open an HSA with the bank designated by MCHCP.

1. Subscribers who enroll in the HSA Plan during open enrollment who have a balance in a health care FSA on January 1 of the new plan year cannot receive an HSA contribution from MCHCP until after the health care FSA grace period ends March 15.

(B) A new employee or subscriber electing coverage due to a life event or loss of employer-sponsored coverage with an effective date after the MCHCP contribution will receive an applicable prorated contribution. Unless a subscriber is eligible for a special enrollment period, a subscriber will not be able to voluntarily change his/her plan selection.

(C) A subscriber who moves from subscriber-only coverage to another coverage level with an effective date after the MCHCP contribution will receive an applicable prorated contribution based on the increased level of coverage.

(D) If a subscriber moves from another coverage level to subscriber-only coverage, cancels all coverage, or MCHCP terminates coverage and has received an HSA contribution, MCHCP will not request a re-payment of the contribution.

(E) If both spouses are state employees covered by MCHCP and they both enroll in an HSA Plan, they must each have a separate HSA. The maximum contribution MCHCP will make for the family is six hundred dollars (\$600) regardless of the number of HSAs or the number of children covered under the HSA Plan for either parent. MCHCP will consider married state employees as one (1) family and will not make two (2) family contributions to both spouses or one (1) family contribution and one (1) individual contribution. MCHCP will make a maximum three hundred dollar (\$300) contribution to each spouse to total a maximum of six hundred dollars (\$600).

(F) The MCHCP contributions will be deposited into the subscriber's HSA as follows:

1. The January deposit will be made on the third Monday of the month, or the first working day after the third Monday if the third Monday is a holiday;

2. The April deposit will be made on the first Monday in April; and

3. Other deposits will be made on the first Monday of the month in which coverage is effective, or the first working day after the first Monday of the month coverage is effective if the first Monday is a state holiday.

AUTHORITY: sections 103.059 and 103.080.3., RSMo 2016. Emergency rule filed Dec. 22, 2008, effective Jan. 1, 2009, expired June 29, 2009. Original rule filed Dec. 22, 2008, effective June 30, 2009. For intervening history, please consult the Code of State Regulations. Emergency amendment filed Oct. 26, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material is published in this issue of the Missouri Register.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

**Title 22—MISSOURI CONSOLIDATED
HEALTH CARE PLAN
Division 10—Health Care Plan
Chapter 2—State Membership**

EMERGENCY AMENDMENT

22 CSR 10-2.089 Pharmacy Employer Group Waiver Plan for Medicare Primary Members. The Missouri Consolidated Health Care Plan is amending section (1).

PURPOSE: This emergency amendment revises Medicare Part D coverage stage and copayment amounts.

EMERGENCY STATEMENT: This emergency amendment must be in place by January 1, 2021, in accordance with the new plan year. Therefore, this emergency amendment is necessary to serve a compelling governmental interest of protecting members (employees, retirees, officers, and their families) enrolled in the Missouri Consolidated Health Care Plan (MCHCP) from the unintended consequences of confusion regarding eligibility or availability of benefits

and will allow members to take advantage of opportunities for reduced premiums for more affordable options without which they may forgo coverage. Further, it clarifies member eligibility and responsibility for various types of eligible charges, beginning with the first day of coverage for the new plan year. It may also help ensure that inappropriate claims are not made against the state and help protect the MCHCP and its members from being subjected to unexpected and significant financial liability and/or litigation. It is imperative that this amendment be filed as an emergency amendment to maintain the integrity of the current health care plan. This emergency amendment fulfills the compelling governmental interest of offering access to more convenient and affordable medical services to members as one (1) method of protecting the MCHCP trust fund from more costly expenses. This emergency amendment reflects changes made to the plan by the Missouri Consolidated Health Care Plan Board of Trustees. A proposed amendment, which covers the same material, is published in this issue of the Missouri Register. This emergency amendment complies with the protections extended by the Missouri and United States Constitutions and limits its scope to the circumstances creating the emergency. The MCHCP follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances. This emergency amendment was filed October 26, 2020, becomes effective January 1, 2021, and expires June 29, 2021.

(1) The pharmacy benefit for Medicare primary non-active members is provided through a Pharmacy Employer Group Waiver Plan (EGWP) as regulated by the Centers for Medicare and Medicaid Services herein after referred to as the Medicare Prescription Drug Plan.

(F) The Medicare Prescription Drug Plan is comprised of a Medicare Part D prescription drug plan contracted by MCHCP and some non-Part D medications that are not normally covered by a Medicare Part D prescription drug plan. The requirements for the Medicare Part D prescription drug plan are as follows:

1. The Centers for Medicare and Medicaid Services regulates the Medicare Part D prescription drug program. The Medicare Prescription Drug Plan abides by those regulations;

2. Initial Coverage Stage. Until a member's total yearly Part D prescription drug costs reach [four thousand twenty dollars (\$4,020)] **four thousand one hundred thirty dollars (\$4,130)**, the member will pay the following copayments:

A. Preferred Formulary Generic Drugs: thirty-one- (31-) day supply has a ten dollar (\$10) copayment; sixty- (60-) day supply has a twenty dollar (\$20) copayment; ninety- (90-) day supply at retail has a thirty dollar (\$30) copayment; and a ninety- (90-) day supply through home delivery has a twenty-five dollar (\$25) copayment;

B. Preferred Formulary Brand Drugs: thirty-one- (31-) day supply has a forty dollar (\$40) copayment; sixty- (60-) day supply has an eighty (\$80) dollar copayment; ninety- (90-) day supply at retail has a one hundred twenty (\$120) dollar copayment; and a ninety- (90-) day supply through home delivery has a one hundred (\$100) dollar copayment; and

C. Non-preferred Formulary Drugs and approved excluded drugs: thirty-one- (31-) day supply has a one hundred dollar (\$100) copayment; sixty- (60-) day supply has a two hundred dollar (\$200) copayment; ninety- (90-) day supply at retail has a three hundred dollar (\$300) copayment; and a ninety- (90-) day supply through home delivery has a two hundred fifty dollar (\$250) copayment;

3. Coverage Gap Stage. After a member's total yearly Part D prescription drug costs exceed [four thousand twenty dollars (\$4,020)] **four thousand one hundred thirty dollars (\$4,130)** and remain below [six thousand three hundred fifty dollars (\$6,350)] **six thousand five hundred fifty dollars (\$6,550)**, the member will continue to pay the same cost-sharing amount as in the Initial Coverage stage until the yearly out-of-pocket Part D prescription drug costs reach [six thousand three hundred fifty dollars (\$6,350)] **six thousand five hundred fifty dollars (\$6,550)**;

4. Catastrophic Coverage Stage. After a member's total yearly out-of-pocket Part D prescription drug costs reach *[six thousand three hundred fifty dollars (\$6,350)]* **six thousand five hundred fifty dollars (\$6,550)**, the member will pay the greater of—

A. Five percent (5%) coinsurance or a *[three dollar and sixty cent (\$3.60)]* **three dollar and seventy cent (\$3.70)** copayment for covered generic drugs (including brand drugs treated as generics), with a maximum not to exceed the standard copayment during the Initial Coverage stage; or

B. Five percent (5%) coinsurance or an *[eight dollar and ninety-five cent (\$8.95)]* **nine dollar and twenty cent (\$9.20)** copayment for all other covered drugs, with a maximum not to exceed the standard copayment during the Initial Coverage stage; and

5. Amounts paid by the member or the plan for non-Part D prescription drugs will not count toward total Part D prescription drug costs or total Part D prescription drug out-of-pocket costs.

AUTHORITY: section 103.059, RSMo 2016. Emergency rule filed Oct. 30, 2013, effective Jan. 1, 2014, expired June 29, 2014. Original rule filed Oct. 30, 2013, effective June 30, 2014. For intervening history, please consult the Code of State Regulations. Emergency amendment filed Oct. 26, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material is published in this issue of the Missouri Register.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

**Title 22—MISSOURI CONSOLIDATED
HEALTH CARE PLAN
Division 10—Health Care Plan
Chapter 3—Public Entity Membership**

EMERGENCY AMENDMENT

22 CSR 10-3.030 Public Entity Membership Agreement and Participation Period. The Missouri Consolidated Health Care Plan is amending section (1).

PURPOSE: This emergency amendment revises participation and contribution requirements for dental coverage.

EMERGENCY STATEMENT: This emergency amendment must be in place by January 1, 2021, in accordance with the new plan year. Therefore, this emergency amendment is necessary to serve a compelling governmental interest of protecting members (public entity employee members, retirees, and their families) enrolled in the Missouri Consolidated Health Care Plan (MCHCP) from the unintended consequences of confusion regarding eligibility or availability of benefits and will allow members to take advantage of opportunities for reduced premiums for more affordable options without which they may forgo coverage. Further, it clarifies member eligibility and responsibility for various types of eligible charges, beginning with the first day of coverage for the new plan year. It may also help ensure that inappropriate claims are not made against the state and help protect the MCHCP and its members from being subjected to unexpected and significant financial liability and/or litigation. It is imperative that this amendment be filed as an emergency amendment to maintain the integrity of the current health care plan. This emergency amendment fulfills the compelling governmental interest of offering access to more convenient and affordable medical services to public entity employee members, retirees, and their families as one (1)

method of protecting the MCHCP trust fund from more costly expenses. This emergency amendment reflects changes made to the plan by the Missouri Consolidated Health Care Plan Board of Trustees. A proposed amendment, which covers the same material, is published in this issue of the Missouri Register. This emergency amendment complies with the protections extended by the Missouri and United States Constitutions and limits its scope to the circumstances creating the emergency. The MCHCP follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances. This emergency amendment was filed October 26, 2020, becomes effective January 1, 2021, and expires June 29, 2021.

(1) The participation agreement, these rules, and applicable provisions of law constitute the membership agreement between a public entity and the Missouri Consolidated Health Care Plan (MCHCP).

(A) By applying for coverage under MCHCP, a public entity agrees that—

1. A public entity must make health care coverage available to all eligible employees, their dependents, former employees entitled to a future retirement benefit, and retirees;

2. MCHCP will be the only health care offering made to its eligible members;

3. The public entity shall contribute at least fifty percent (50%) of the lowest-cost employee-only premium per month toward each active employee's premium for the plan(s) offered through MCHCP. There is no contribution requirement for dependents or retirees;

4. *[The public entity shall contribute at least fifty percent (50%) toward the employee-only dental premium per month. One hundred percent (100%) of the employees enrolled in the medical plan and fifty percent (50%) of dependents enrolled in the medical plan must participate in the dental plan. The number of employees enrolled in the dental plan must be equal to or exceed the number in the medical plan, but the same employees do not have to be enrolled in both plans;] There are no participation or contribution requirements for dental coverage;*

5. There are no participation or contribution requirements for vision coverage;

6. The Employee Assistance Program is paid by the employer and requires one hundred percent (100%) participation of employees eligible for medical coverage and can be expanded to additional classifications;

7. For public entities with fewer than twenty-five (25) employees, the public entity shall only offer one (1) MCHCP medical plan choice to its employees. For public entities with twenty-five (25) or more employees, the public entity may offer two (2) MCHCP medical plan choices;

8. For public entities with more than a total of three (3) employees, at least seventy-five percent (75%) of all eligible employees must enroll in MCHCP. If an employee declines coverage, s/he must submit a form stating coverage is waived. If the employee is waiving coverage because s/he is covered under another group health plan, Medicare or Medicaid, the employee must submit proof of other coverage. An employee with other group coverage, Medicare, or Medicaid is exempt from the seventy-five percent (75%) enrollment participation requirement. A participation audit will be conducted annually to ensure the participation requirement is met;

9. Any individual eligible as an employee may be covered as either an employee or dependent, but not both. Employees enrolled as dependents will not be considered as eligible employees;

10. A public entity may apply a probationary period, not to exceed applicable federal guidelines, before benefits become effective; and

11. A public entity must notify MCHCP of a member's termination within thirty (30) days of the termination.

AUTHORITY: section 103.059, RSMo [2000] 2016. Emergency rule filed Dec. 20, 2004, effective Jan. 1, 2005, expired June 29, 2005.

Original rule filed Dec. 20, 2004, effective June 30, 2005. For intervening history, please consult the Code of State Regulations. Emergency amendment filed Oct. 26, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material is published in this issue of the Missouri Register.

PUBLIC COST: *This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.*

PRIVATE COST: *This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.*

**Title 22—MISSOURI CONSOLIDATED
HEALTH CARE PLAN
Division 10—Health Care Plan
Chapter 3—Public Entity Membership
EMERGENCY AMENDMENT**

22 CSR 10-3.055 Health Savings Account Plan Benefit Provisions and Covered Charges. The Missouri Consolidated Health Care Plan is amending section (3), adding section (10), and renumbering as necessary.

PURPOSE: *This emergency amendment revises the out-of-pocket maximum for individual family members and adds one hundred percent (100%) coverage of virtual visits offered through the vendor's telehealth tool.*

EMERGENCY STATEMENT: *This emergency amendment must be in place by January 1, 2021, in accordance with the new plan year. Therefore, this emergency amendment is necessary to serve a compelling governmental interest of protecting members (public entity employee members, retirees, and their families) enrolled in the Missouri Consolidated Health Care Plan (MCHCP) from the unintended consequences of confusion regarding eligibility or availability of benefits and will allow members to take advantage of opportunities for reduced premiums for more affordable options without which they may forgo coverage. Further, it clarifies member eligibility and responsibility for various types of eligible charges, beginning with the first day of coverage for the new plan year. It may also help ensure that inappropriate claims are not made against the state and help protect the MCHCP and its members from being subjected to unexpected and significant financial liability and/or litigation. It is imperative that this amendment be filed as an emergency amendment to maintain the integrity of the current health care plan. This emergency amendment fulfills the compelling governmental interest of offering access to more convenient and affordable medical services to public entity employee members, retirees, and their families as one (1) method of protecting the MCHCP trust fund from more costly expenses. This emergency amendment reflects changes made to the plan by the Missouri Consolidated Health Care Plan Board of Trustees. A proposed amendment, which covers the same material, is published in this issue of the Missouri Register. This emergency amendment complies with the protections extended by the Missouri and United States Constitutions and limits its scope to the circumstances creating the emergency. The MCHCP follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances. This emergency amendment was filed October 26, 2020, becomes effective January 1, 2021, and expires June 29, 2021.*

(3) Out-of-pocket maximum.

(A) The family out-of-pocket maximum applies when two (2) or more family members are covered. The family out-of-pocket maxi-

imum must be met before the plan begins to pay one hundred percent (100%) of all covered charges for any covered family member. Out-of-pocket maximums are per calendar year, as follows:

1. Network out-of-pocket maximum for individual—four thousand nine hundred fifty dollars (\$4,950);

2. Network out-of-pocket maximum for family—nine thousand nine hundred dollars (\$9,900). Any individual family member need only incur a maximum of eight thousand [one hundred fifty dollars (\$8,150)] **eight thousand five hundred fifty dollars (\$8,550)** before the plan begins paying one hundred percent (100%) of covered charges for that individual;

3. Non-network out-of-pocket maximum for individual—nine thousand nine hundred dollars (\$9,900); and

4. Non-network out-of-pocket maximum for family—nineteen thousand eight hundred dollars (\$19,800).

(10) Virtual visits offered through the vendor's telehealth tool are covered at one hundred percent (100%).

~~[(10)]~~**(11)** Newborn's claims will be subject to deductible and coinsurance.

~~[(11)]~~**(12)** Each subscriber will have access to payment information of the family unit only when authorization is granted by the adult covered dependent(s).

~~[(12)]~~**(13)** Expenses toward the deductible and out-of-pocket maximum will be transferred if the member changes medical plans or continues enrollment under another subscriber's plan within the same plan year.

~~[(13)]~~**(14)** Maximum plan payment—Non-network medical claims that are not otherwise subject to a contractual discount arrangement are processed at one hundred ten percent (110%) of Medicare reimbursement for non-network professional claims and following the claims administrator's standard practice for non-network facility claims. Members may be held liable for the amount of the fee above the allowed amount.

~~[(14)]~~**(15)** Any claim must be initially submitted within twelve (12) months following the date of service, unless otherwise specified in the network provider contract. The plan reserves the right to deny claims not timely filed. A provider initiated correction to the originally filed claim must be submitted within the timeframe agreed in the provider contract, but not to exceed three hundred sixty-five (365) days from adjudication of the originally filed claim. Any claims reprocessed as primary based on action taken by Medicare or Medicaid must be initiated within three (3) years of the claim being incurred.

~~[(15)]~~**(16)** For a member who is an inpatient on the last calendar day of a plan year and remains an inpatient into the next plan year, the prior plan year's applicable deductible and/or coinsurance amounts will apply to the in-hospital facility and related ancillary charges until the member is discharged.

~~[(16)]~~**(17)** A subscriber does not qualify for the HSA Plan if s/he is claimed as a dependent on another person's tax return or, except for the plans listed in section (17) of this rule, is covered under or enrolled in any other health plan that is not a high deductible health plan, including, but not limited to, the following types of insurance plans or programs:

(A) Medicare (unless Medicare is secondary coverage to MCHCP);

(B) TRICARE;

(C) A health care flexible spending account (FSA), with the exception of participation in the premium-only, limited-purpose health FSA, and dependent care section;

(D) Health reimbursement account (HRA); or

(E) If the member has received medical benefits from The Department of Veterans Affairs (VA) at any time during the previous three (3) months, unless the medical benefits received consist solely of disregarded coverage or preventive care.

[(17)](18) A subscriber may qualify for this plan even if s/he is covered by any of the following:

- (A) Drug discount card;
- (B) Accident insurance;
- (C) Disability insurance;
- (D) Dental insurance;
- (E) Vision insurance; or
- (F) Long-term care insurance.

[(18)](19) Services performed in a country other than the United States may be covered if the service is included in 22 CSR 10-3.057. Emergency and urgent care services are covered as a network benefit. All other non-emergency services are covered as determined by the claims administrator. If the service is provided by a non-network provider, the member may be required to provide payment to the provider and then file a claim for reimbursement subject to timely filing limits.

AUTHORITY: sections 103.059 and 103.080.3., RSMo 2016. Emergency rule filed Dec. 22, 2009, effective Jan. 1, 2010, expired June 29, 2010. Original rule filed Jan. 4, 2010, effective June 30, 2010. For intervening history, please consult the Code of State Regulations. Emergency amendment filed Oct. 26, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material is published in this issue of the Missouri Register.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

**Title 22—MISSOURI CONSOLIDATED
HEALTH CARE PLAN
Division 10—Health Care Plan
Chapter 3—Public Entity Membership**

EMERGENCY AMENDMENT

22 CSR 10-3.058 PPO 750 Plan Benefit Provisions and Covered Charges. The Missouri Consolidated Health Care Plan is amending section (5).

PURPOSE: This emergency amendment adds one hundred percent (100%) coverage of virtual visits offered through the vendor's telehealth tool.

EMERGENCY STATEMENT: This emergency amendment must be in place by January 1, 2021, in accordance with the new plan year. Therefore, this emergency amendment is necessary to serve a compelling governmental interest of protecting members (public entity employee members, retirees, and their families) enrolled in the Missouri Consolidated Health Care Plan (MCHCP) from the unintended consequences of confusion regarding eligibility or availability of benefits and will allow members to take advantage of opportunities for reduced premiums for more affordable options without which they may forgo coverage. Further, it clarifies member eligibility and responsibility for various types of eligible charges, beginning with the first day of coverage for the new plan year. It may also help ensure

that inappropriate claims are not made against the state and help protect the MCHCP and its members from being subjected to unexpected and significant financial liability and/or litigation. It is imperative that this amendment be filed as an emergency amendment to maintain the integrity of the current health care plan. This emergency amendment fulfills the compelling governmental interest of offering access to more convenient and affordable medical services to public entity employee members, retirees, and their families as one (1) method of protecting the MCHCP trust fund from more costly expenses. This emergency amendment reflects changes made to the plan by the Missouri Consolidated Health Care Plan Board of Trustees. A proposed amendment, which covers the same material, is published in this issue of the Missouri Register. This emergency amendment complies with the protections extended by the Missouri and United States Constitutions and limits its scope to the circumstances creating the emergency. The MCHCP follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances. This emergency amendment was filed October 26, 2020, becomes effective January 1, 2021, and expires June 29, 2021.

(5) The following services are not subject to deductible, coinsurance, or copayment requirements and will be paid at one hundred percent (100%) when provided by a network provider:

- (D) Four (4) Diabetes Self-Management Education visits; *[and]*
- (E) Sterilization procedure for men./.; **and**
- (F) **Virtual visits offered through the vendor's telehealth tool.**

AUTHORITY: section 103.059, RSMo 2016. Emergency rule filed Oct. 31, 2018, effective Jan. 1, 2019, expired June 29, 2019. Original rule filed Oct. 31, 2018, effective May 30, 2019. Emergency amendment filed Oct. 30, 2019, effective Jan. 1, 2020, expired June 28, 2020. Amended: Filed Oct. 30, 2019, effective May 30, 2020. Emergency amendment filed Oct. 26, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material is published in this issue of the Missouri Register.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

**Title 22—MISSOURI CONSOLIDATED
HEALTH CARE PLAN
Division 10—Health Care Plan
Chapter 3—Public Entity Membership**

EMERGENCY AMENDMENT

22 CSR 10-3.059 PPO 1250 Plan Benefit Provisions and Covered Charges. The Missouri Consolidated Health Care Plan is amending section (5).

PURPOSE: This emergency amendment adds one hundred percent (100%) coverage of virtual visits offered through the vendor's telehealth tool.

EMERGENCY STATEMENT: This emergency amendment must be in place by January 1, 2021, in accordance with the new plan year. Therefore, this emergency amendment is necessary to serve a compelling governmental interest of protecting members (public entity employee members, retirees, and their families) enrolled in the Missouri Consolidated Health Care Plan (MCHCP) from the unintended consequences of confusion regarding eligibility or availability of benefits and will allow members to take advantage of opportunities

for reduced premiums for more affordable options without which they may forgo coverage. Further, it clarifies member eligibility and responsibility for various types of eligible charges, beginning with the first day of coverage for the new plan year. It may also help ensure that inappropriate claims are not made against the state and help protect the MCHCP and its members from being subjected to unexpected and significant financial liability and/or litigation. It is imperative that this amendment be filed as an emergency amendment to maintain the integrity of the current health care plan. This emergency amendment fulfills the compelling governmental interest of offering access to more convenient and affordable medical services to public entity employee members, retirees, and their families as one (1) method of protecting the MCHCP trust fund from more costly expenses. This emergency amendment reflects changes made to the plan by the Missouri Consolidated Health Care Plan Board of Trustees. A proposed amendment, which covers the same material, is published in this issue of the **Missouri Register**. This emergency amendment complies with the protections extended by the **Missouri and United States Constitutions** and limits its scope to the circumstances creating the emergency. The MCHCP follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances. This emergency amendment was filed October 26, 2020, becomes effective January 1, 2021, and expires June 29, 2021.

(5) The following services are not subject to deductible, coinsurance, or copayment requirements and will be paid at one hundred percent (100%) when provided by a network provider:

- (D) Four (4) Diabetes Self-Management Education visits; *[and]*
- (E) Sterilization procedure for men^{f.}; **and**
- (F) **Virtual visits offered through the vendor's telehealth tool.**

AUTHORITY: section 103.059, RSMo 2016. Emergency rule filed Oct. 31, 2018, effective Jan. 1, 2019, expired June 29, 2019. Original rule filed Oct. 31, 2018, effective May 30, 2019. Emergency amendment filed Oct. 30, 2019, effective Jan. 1, 2020, expired June 28, 2020. Amended: Filed Oct. 30, 2019, effective May 30, 2020. Emergency amendment filed Oct. 26, 2020, effective Jan. 1, 2021, expires June 29, 2021. A proposed amendment covering this same material is published in this issue of the **Missouri Register**.

PUBLIC COST: This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

PRIVATE COST: This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

The Secretary of State shall publish all executive orders beginning January 1, 2003, pursuant to section 536.035.2, RSMo.

GOVERNOR'S PROCLAMATION

WHEREAS, on March 13, 2020, I signed Executive Order 20-02 declaring a state of emergency in response to the spread of COVID-19 virus; and

WHEREAS, due to COVID-19, the General Assembly was only able to meet in limited fashion during the Second Regular Session of the One Hundredth General Assembly; and

WHEREAS, the United States Congress passed, and the President of the United States signed into law, four bills that awarded the State of Missouri funding including the Coronavirus Preparedness and Response Supplemental Appropriations Act, the Families First Coronavirus Response Act, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, and the Paycheck Protection Program and Health Care Enhancement Act; and

WHEREAS, the aforementioned federal funding was intended for several different programs and grants across state government; and

WHEREAS, the General Assembly Truly Agreed to and Finally Passed the budget on May 8, 2020; and

WHEREAS, since the time the budget was passed by the General Assembly, additional funding has been made available to the State of Missouri through grants provided by these federal laws to help respond to COVID-19; and

WHEREAS, there is an immediate need to appropriate additional resources to respond to COVID-19 and to ensure the health and safety of the public.

NOW THEREFORE, on the extraordinary occasion that exists in the State of Missouri:

I, MICHAEL L. PARSON, GOVERNOR OF THE STATE OF MISSOURI, pursuant to the authority vested in me as Governor by the Constitution of the State of Missouri, do, by this Proclamation, convene the One Hundredth General Assembly of the State of Missouri in the Second Extra Session of the Second Regular Session; and

I HEREBY call upon the Senators and Representatives of said General Assembly to meet in the State Capitol in the City of Jefferson at the hour of 12:00 p.m. on Thursday, November 5, 2020; and

I HEREBY state that the action of said General Assembly is deemed necessary concerning each matter specifically designated and limited hereinafter as follows:

1. To enact legislation providing for the supplemental appropriation of additional state and federal resources, including such resources necessary to respond to COVID-19;
2. To allow the Senate to consider appointments to boards, commissions, departments, and divisions that require the advice and consent of the Senate; and
3. Such additional and other matters as may be recommended by the Governor by special message to the General Assembly after it shall have been convened.



IN WITNESS WHEREOF, I have hereunto set my hand and caused to be affixed the Great Seal of the State of Missouri, in the City of Jefferson, on this 21st day of October, 2020.

MICHAEL L. PARSON
GOVERNOR

ATTEST:


JOHN R. ASHCROFT
SECRETARY OF STATE

**EXECUTIVE ORDER
20-18**

TO ALL DEPARTMENTS AND AGENCIES:

This is to advise that state offices of the executive branch under the purview of the Governor will be closed on Friday, November 27, 2020.

IN WITNESS WHEREOF, I have hereunto set my hand and caused to be affixed the Great Seal of the State of Missouri, in the City of Jefferson, on this 30th day of October, 2020.



MICHAEL L. PARSON
GOVERNOR

ATTEST:

JOHN R. ASHCROFT
SECRETARY OF STATE